[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 31825
1. Mouw KW, Haraf DJ, Stenson KM, Cohen EE, Xi X, Witt ME, List M, Blair EA, Vokes EE, Salama JK: Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg; 2010 Dec;136(12):1226-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.
  • PATIENTS: one hundred eighty-four patients with locoregionally advanced head and neck cancer.
  • Factors that were associated with worse speaking outcomes included female sex, smoking history, hypopharyngeal or laryngeal primary sites, and poor response to induction chemotherapy; factors associated with worse swallowing outcomes included advanced patient age, poor performance status, primary site, and neck dissection.
  • CONCLUSIONS: among patients successfully treated for locoregionally advanced cancers of the head and neck, several factors correlate with speaking and swallowing outcomes.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21173372.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Kunisaki C, Makino H, Takagawa R, Oshima T, Nagano Y, Fujii S, Otsuka Y, Akiyama H, Ono HA, Kosaka T, Ichikawa Y, Shimada H: Impact of palliative gastrectomy in patients with incurable advanced gastric cancer. Anticancer Res; 2008 Mar-Apr;28(2B):1309-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of palliative gastrectomy in patients with incurable advanced gastric cancer.
  • BACKGROUND: The efficacy of palliative gastrectomy for incurable advanced gastric cancer remains debatable.
  • CONCLUSION: A randomized controlled study should be conducted in advanced gastric cancer patients with a single non-curative factor to confirm the usefulness of palliative gastrectomy followed by chemotherapy shown here.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505071.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


3. Bundred N: Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. Cancer Invest; 2005;23(2):173-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
  • Phase III clinical trials have demonstrated the clinical benefit of fulvestrant in the endocrine treatment of breast cancer.
  • For the first-line therapy of advanced breast cancer in postmenopausal women, fulvestrant was shown to be active and well tolerated in a trial that compared fulvestrant 250 mg once monthly and tamoxifen 20 mg once daily.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813510.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Triazoles; 22X328QOC4 / fulvestrant; 2Z07MYW1AZ / anastrozole; 4TI98Z838E / Estradiol
  • [Number-of-references] 46
  •  go-up   go-down


Advertisement
4. Guo H, Zhang R, Yang Q, Zhang L, Yang K, Tian J: [A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer.]. Zhongguo Fei Ai Za Zhi; 2009 Dec 20;12(12):1260-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer.].
  • BACKGROUND: It was unclear whether advanced non-small cell lung cancer (NSCLC) patients could benefit from erlotinib therapy.
  • CONCLUSIONS: Advanced non-small cell lung cancer patients could benefit from Erlotinib therapy, but the incidence of skin rash and diarrhea was significantly increased, and in the absence of damage to the blood system, serious liver and kidney damage, cardiac toxicity, etc, there were no difference with placebo.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723380.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Uruga H, Kishi K, Fujii T, Beika Y, Enomoto T, Takaya H, Miyamoto A, Morokawa N, Kurosaki A, Yoshimura K: Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. Intern Med; 2010;49(2):103-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis.
  • OBJECTIVE: To retrospectively evaluate the efficacy and safety of gefitinib in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations.
  • METHODS AND PATIENTS: Nine patients aged 70 years or older who had advanced NSCLC with mutations of the epidermal growth factor receptor gene were treated with gefitinib, 250 mg daily.


6. Tsuji A, Shima Y, Morita S, Uchida M, Okamoto K, Morita M, Horimi T, Shirasaka T: Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study. Anticancer Res; 2008 Mar-Apr;28(2B):1433-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
  • BACKGROUND: We have reported the efficacy and safety of S-1 combined with low-dose consecutive cisplatin therapy for advanced and recurrent gastric cancer, but the regimen was difficult because daily cisplatin administration was necessary.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505092.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Weiss J, Moghanaki D, Plastaras JP, Haller DG: Improved patient and regimen selection in locally advanced rectal cancer: who, how, and what next? Clin Colorectal Cancer; 2009 Oct;8(4):194-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved patient and regimen selection in locally advanced rectal cancer: who, how, and what next?
  • Before the advent of neoadjuvant chemoradiation therapy (NCRT) for locally advanced rectal cancer, local failure represented half of treatment failures.
  • The German Rectal Cancer Study Group trial demonstrated that NCRT along with total mesorectal excision can improve local control and the rate of sphincter-preserving surgery.
  • Thus, the National Comprehensive Cancer Network now recommends NCRT as the standard of care for stage III and IV rectal cancer.
  • The prognosis of rectal cancer is stage dependent, and 2 major analyses question whether T1/2 N1 and T3 N0 patients benefit from NCRT.
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoadjuvant Therapy. Neoplasm Staging. Patient Selection. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822509.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


8. Coulter ID, Hardy ML, Morton SC, Hilton LG, Tu W, Valentine D, Shekelle PG: Antioxidants vitamin C and vitamin e for the prevention and treatment of cancer. J Gen Intern Med; 2006 Jul;21(7):735-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antioxidants vitamin C and vitamin e for the prevention and treatment of cancer.
  • OBJECTIVE: To evaluate the evidence of the supplements vitamin C and vitamin E for treatment and prevention of cancer.
  • In the ATBC Cancer Prevention Study Group, no statistically significant effect of treatment was seen for any cancer individually, and our pooled relative risk (regardless of tumor type) for alpha-tocopherol alone was 0.91 (95% confidence interval [CI]: 0.74, 1.12).
  • In the Linxian General Population Trial, the relative risks for cancer death for vitamin C (combined with molybdenum) was 1.06 (95% CI: 0.92, 1.21) and for vitamin E (combined with beta-carotene and selenium) was 0.87 (95% CI: 0.76, 1.00).
  • We identified only 3 studies that reported statistically significant beneficial results: vitamin C (in combination with BCG) was found to be beneficial in a single trial of bladder cancer and vitamin E (in combination with omega-3 fatty acid) increased survival in patients with advanced cancer.
  • In the ATBC trial, in analyses of 6 individual cancers, the prevention of prostate cancer in subjects treated with alpha-tocopherol was statistically significant (RR=0.64, 95% CI: 0.44, 0.94).
  • CONCLUSIONS: The systematic review of the literature does not support the hypothesis that the use of supplements of vitamin C or vitamin E in the doses tested helps prevent and/or treat cancer in the populations tested.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1868-9 [11106670.001]
  • [Cites] N Engl J Med. 1994 Jul 21;331(3):141-7 [8008027.001]
  • [Cites] Lancet. 2002 Jul 6;360(9326):23-33 [12114037.001]
  • [Cites] N Engl J Med. 1979 Sep 27;301(13):687-90 [384241.001]
  • [Cites] Cancer. 1981 Mar 1;47(5 Suppl):1226-40 [7237379.001]
  • [Cites] Cancer. 1982 Oct 1;50(7):1434-9 [7049351.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):137-41 [3880867.001]
  • [Cites] Acta Vitaminol Enzymol. 1984;6(3):175-82 [6524577.001]
  • [Cites] Nutr Rev. 1985 May;43(5):146-7 [3897919.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4701-5 [3293777.001]
  • [Cites] Ann Intern Med. 1991 May 15;114(10):909-10 [2014955.001]
  • [Cites] Dis Colon Rectum. 1993 Mar;36(3):227-34 [8449125.001]
  • [Cites] Gut. 1993 Jul;34(7):963-7 [8344584.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1492-8 [8360932.001]
  • [Cites] J Urol. 1994 Jan;151(1):21-6 [8254816.001]
  • [Cites] N Engl J Med. 1994 Apr 14;330(15):1029-35 [8127329.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):2029s-2031s [8137333.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):167-72 [8049639.001]
  • [Cites] Ann Epidemiol. 1993 Nov;3(6):577-85 [7921303.001]
  • [Cites] JAMA. 1995 Feb 1;273(5):408-12 [7823387.001]
  • [Cites] Biometrics. 1994 Dec;50(4):1088-101 [7786990.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 6;88(21):1560-70 [8901854.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):197-205 [10782653.001]
  • [Cites] BMJ. 1997 Sep 13;315(7109):629-34 [9310563.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):395-402 [9445198.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):440-6 [9521168.001]
  • [Cites] Scand J Gastroenterol. 1998 Mar;33(3):294-300 [9548624.001]
  • [Cites] Digestion. 1998;59(2):148-56 [9586828.001]
  • [Cites] Lancet. 1998 Aug 22;352(9128):609-13 [9746022.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):489-93 [10385137.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):37-42 [10391561.001]
  • [Cites] JAMA. 2005 Mar 16;293(11):1338-47 [15769967.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):56-65 [15998891.001]
  • [Cites] Cancer Causes Control. 2000 Dec;11(10):933-9 [11142528.001]
  • (PMID = 16808775.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 290-97-0001
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 1406-18-4 / Vitamin E; PQ6CK8PD0R / Ascorbic Acid
  • [Other-IDs] NLM/ PMC1924689
  •  go-up   go-down


9. Long JA, Descotes JL, Rambeaud JJ: [Kidney cancer diagnosis]. Rev Prat; 2007 Mar 31;57(6):603-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kidney cancer diagnosis].
  • [Transliterated title] Diagnostic du cancer du rein.
  • Currently, kidney cancer is in most cases fortuitously diagnosed by ultrasound or abdominal computed tomography, performed for non-specific clinical signs.
  • The late-developing clinical signs are suggestive of an advanced tumour stage.

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593784.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 10
  •  go-up   go-down


10. Oztop I, Alacacioglu A, Unek IT, Tarhan O, Somali I, Cokmert S, Yavuzsen T, Yilmaz U: Gemcitabine plus infusional 5-fluorouracil and high dose leucovorin in advanced stage pancreatic cancer. J BUON; 2010 Jul-Sep;15(3):462-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine plus infusional 5-fluorouracil and high dose leucovorin in advanced stage pancreatic cancer.
  • PURPOSE: Advanced pancreatic cancer (APC) has a poor prognosis and chemotherapy remains the primary treatment modality.
  • Gemcitabine (GEM) and 5-fluorouracil (5-FU) are the most active drugs in the treatment of pancreatic cancer.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941811.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG: A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. Cancer Chemother Pharmacol; 2009 Feb;63(3):477-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
  • PURPOSE: To evaluate the safety, pharmacokinetics and determine the recommended dose of the selective apoptotic antineoplastic drug, OSI-461 administered on a twice-daily regimen to patients with advanced solid malignancies.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3338-42 [10910034.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):383-91 [11279519.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3961-8 [11358813.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Nov;299(2):583-92 [11602670.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3100-4 [12374677.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):60-7 [16432163.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8442-7 [16166323.001]
  • [Cites] Biochem Pharmacol. 2002 Nov 1;64(9):1325-36 [12392815.001]
  • [Cites] Am J Clin Oncol. 2006 Aug;29(4):395-8 [16891869.001]
  • [Cites] J Thorac Oncol. 2006 Mar;1(3):218-25 [17409860.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):673-8 [17409935.001]
  • [Cites] Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94 [12406645.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):611-6 [12479221.001]
  • [Cites] Pharmacogenetics. 2003 Jan;13(1):19-28 [12544509.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3454-61 [12972520.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4972-82 [14581372.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6710-21 [15475462.001]
  • [Cites] Cancer Res. 1976 Jan;36(1):60-6 [174814.001]
  • [Cites] J Clin Pharmacol. 1992 Dec;32(12):1089-95 [1487546.001]
  • [Cites] J Clin Pharmacol. 1993 Apr;33(4):381-6 [8473554.001]
  • [Cites] FEBS Lett. 1997 Jan 6;400(3):285-8 [9009215.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):34263-71 [9852090.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70 [9861027.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):8-13 [9892175.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1999;135:67-104 [9932481.001]
  • [Cites] Exp Cell Res. 1999 Feb 25;247(1):38-47 [10047446.001]
  • [Cites] Crit Rev Clin Lab Sci. 1999 Aug;36(4):275-328 [10486703.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4559-63 [10493507.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7229-37 [15534096.001]
  • [Cites] Clin Pharmacokinet. 2004;43(15):1127-56 [15568891.001]
  • [Cites] Drug Metab Dispos. 2005 Jan;33(1):94-101 [15475413.001]
  • [Cites] J Cell Biochem. 2005 Feb 1;94(2):336-50 [15526282.001]
  • [Cites] Br J Clin Pharmacol. 2005 Mar;59(3):355-64 [15752382.001]
  • [Cites] BJU Int. 2005 May;95(7):963-8 [15839914.001]
  • [Cites] Clin Lung Cancer. 2005 May;6(6):361-6 [15943897.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):78-89 [10656435.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4136-41 [11051267.001]
  • (PMID = 18509645.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106349-05; United States / NCI NIH HHS / CA / K24 CA106349; United States / NCI NIH HHS / CA / T32 CA082086; United States / NCI NIH HHS / CA / K24 CA106349-05
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 184SNS8VUH / Sulindac; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ NIHMS169572; NLM/ PMC2814254
  •  go-up   go-down


12. Kyriazi S, Collins DJ, Morgan VA, Giles SL, deSouza NM: Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer. Radiographics; 2010 Sep;30(5):1269-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer.
  • Cross-sectional imaging of peritoneal carcinomatosis in patients with advanced ovarian cancer is important for appropriate management but can be compromised by the small size of cancer implants and the complexity of anatomic relationships.
  • Competence in data display methods and ADC calculations also helps improve the accuracy of image interpretation and may aid in the management of patients with advanced ovarian cancer.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Neoplasm Staging / methods. Ovarian Neoplasms / diagnosis. Peritoneal Diseases / diagnosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20833850.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0701533; United Kingdom / Department of Health / / C1060/A10334; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Ward AM, Agar M, Koczwara B: Collaborating or co-existing: a survey of attitudes of medical oncologists toward specialist palliative care. Palliat Med; 2009 Dec;23(8):698-707
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with advanced cancer often have complex care needs requiring collaboration between medical oncology and palliative care providers.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825895.001).
  • [ISSN] 1477-030X
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Coyle EF: Improved muscular efficiency displayed as Tour de France champion matures. J Appl Physiol (1985); 2005 Jun;98(6):2191-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is noteworthy that at age 25 yr, this champion developed advanced cancer, requiring surgeries and chemotherapy.


15. Zitt M, Müller HM, Rochel M, Schwendinger V, Zitt M, Goebel G, Devries A, Margreiter R, Oberwalder M, Zeillinger R, Ofner D: Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers; 2008;25(3):159-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring.
  • The objective of this proof of principle study was to evaluate whether the amount of circulating plasma DNA has the potential to serve as a marker for therapy monitoring during the treatment course of locally advanced rectal cancer patients.
  • The amount of circulating DNA in plasma of rectal cancer patients undergoing preoperative chemoradiation was determined using real-time PCR before chemoradiation, after the end of chemoradiation and at the end of treatment.
  • This study demonstrates that circulating DNA in plasma of rectal cancer patients undergoing preoperative chemoradiation might serve as a surrogate marker to discriminate between responders and nonresponders.
  • [MeSH-major] DNA, Neoplasm / blood. Rectal Neoplasms / blood

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096128.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC3827809
  •  go-up   go-down


16. Koning CC, van Zandwijk N: [Two patients with advanced non-small cell lung cancer (stage IIIB) who still responded very well to combined chemotherapy and radiotherapy]. Ned Tijdschr Geneeskd; 2005 Jun 4;149(23):1289-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two patients with advanced non-small cell lung cancer (stage IIIB) who still responded very well to combined chemotherapy and radiotherapy].
  • In two patients, men aged 58 and 47 years respectively, advanced non-small cell lung cancer (stage IIIB) with mediastinal and supraclavicular lymph-node metastases was diagnosed.
  • Although not every patient with stage IIIB lung cancer will respond so well to combined treatment, these cases illustrate that intensive treatment may be recommended for selected patients.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15960136.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


17. Fadul N, Kaur G, Zhang T, Palmer JL, Bruera E: Evaluation of the memorial delirium assessment scale (MDAS) for the screening of delirium by means of simulated cases by palliative care health professionals. Support Care Cancer; 2007 Nov;15(11):1271-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Delirium is among the most common neuropsychiatric complications of advanced cancer.
  • The Memorial Delirium Assessment Scale (MDAS) is a widely used and validated screening tool for delirium in cancer patients.

  • MedlinePlus Health Information. consumer health - Delirium.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2000 Nov 15;284(19):2427-9 [11074759.001]
  • [Cites] J Pain Symptom Manage. 1995 May;10(4):287-91 [7602179.001]
  • [Cites] Psychol Med. 1982 May;12(2):397-408 [7100362.001]
  • [Cites] Psychiatry Res. 1988 Jan;23(1):89-97 [3363018.001]
  • [Cites] J Geriatr Psychiatry Neurol. 1992 Jan-Mar;5(1):14-21 [1571069.001]
  • [Cites] Psychosomatics. 2002 May-Jun;43(3):183-94 [12075033.001]
  • [Cites] Palliat Med. 2001 May;15(3):197-206 [11407191.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Jun;16(3):701-14 [12170576.001]
  • [Cites] Palliat Med. 2004 Apr;18(3):184-94 [15198131.001]
  • [Cites] Gen Hosp Psychiatry. 2001 Jan-Feb;23(1):36-40 [11226556.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] J Pain Symptom Manage. 1992 May;7(4):192-5 [1517640.001]
  • [Cites] J Pain Symptom Manage. 2005 Apr;29(4):368-75 [15857740.001]
  • [Cites] Int Psychogeriatr. 1991 Winter;3(2):197-208 [1811773.001]
  • [Cites] Ann Intern Med. 1990 Dec 15;113(12):941-8 [2240918.001]
  • [Cites] Am J Psychiatry. 1988 Mar;145(3):342-5 [3344848.001]
  • [Cites] J Pain Symptom Manage. 2000 Jun;19(6):412-26 [10908822.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2859-67 [10870073.001]
  • [Cites] J Pain Symptom Manage. 1997 Mar;13(3):128-37 [9114631.001]
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):786-94 [10737278.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):835-42 [9024722.001]
  • [Cites] J Pain Symptom Manage. 2001 Jan;21(1):59-68 [11223315.001]
  • [Cites] Int J Psychiatry Med. 1986-1987;16(2):101-11 [3528007.001]
  • [Cites] J Pain Symptom Manage. 1995 Jan;10(1):35-77 [7714346.001]
  • (PMID = 17387520.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Jensen HA, Nielsen HO, Jensen JD, Fristrup CW, Nielsen M, Pfeiffer P: [Treatment of unresectable locally advanced pancreatic cancer with combined radiotherapy and chemotherapy]. Ugeskr Laeger; 2008 Feb 18;170(8):639-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of unresectable locally advanced pancreatic cancer with combined radiotherapy and chemotherapy].
  • INTRODUCTION: Only 10-20% of patients with pancreatic cancer are offered operation with curative intent.
  • If this is not possible, treatment with pre-operative radiotherapy in combination with chemotherapy offers the opportunity to reduce tumor size in patients with locally advanced disease, and possibly resection with curative intent afterwards.
  • MATERIALS AND METHODS: A total of 26 patients with locally advanced unresectable pancreatic cancer were offered a combination of radiotherapy and chemotherapy.
  • Therefore patients with locally advanced unresectable pancreatic cancer should be offered radiotherapy in combination with chemotherapy.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Preoperative Care. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ugeskr Laeger. 2008 Sep 15;170(38):2985; author reply 2986 [18816889.001]
  • (PMID = 18364156.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


19. Vieweg J: Immunotherapy for advanced prostate cancer. Rev Urol; 2007;9 Suppl 1:S29-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy for advanced prostate cancer.
  • The absence of curative therapies for advanced or recurrent forms of prostate cancer mandates continued development of novel, more effective treatment regimens.
  • Due to recent advances in basic and translational research, therapeutic vaccines and monoclonal antibody-based therapies are steadily gaining ground as promising treatment modalities against prostate cancer.
  • The objective of this article is to increase awareness of contemporary immunologic therapies and clinical trials of new biologic reagents against prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5160-8 [10537292.001]
  • [Cites] Novartis Found Symp. 1998;215:92-8; discussion 98-102, 186-90 [9760573.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2444-8 [10811122.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3894-903 [11099318.001]
  • [Cites] J Immunother. 2001 Nov-Dec;24(6):431-46 [11759067.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):2-3 [12540496.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2127-33 [12727829.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2145-9 [12727832.001]
  • [Cites] Cancer Immunol Immunother. 2004 Feb;53(2):64-72 [14593498.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7483-9 [14612549.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2122-32 [15169798.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2227-30 [15294932.001]
  • [Cites] Nat Med. 2004 Sep;10(9):887-92 [15340404.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Expert Opin Biol Ther. 2004 Nov;4(11):1791-801 [15500407.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16885-90 [15548615.001]
  • [Cites] Springer Semin Immunopathol. 2005 Jan;26(3):329-41 [15609005.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3798-807 [15749921.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):239-49 [15766662.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8926-8 [16204008.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):957-9 [16244797.001]
  • [Cites] Eur J Immunol. 2005 Dec;35(12):3694-703 [16252254.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:94-9 [16273357.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] J Transl Med. 2006;4:1 [16390546.001]
  • [Cites] Nat Clin Pract Urol. 2005 Jan;2(1):44-51 [16474576.001]
  • [Cites] Curr Probl Cancer. 1991 Nov-Dec;15(6):299-360 [1760927.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]
  • [Cites] Eur J Immunol. 1993 Oct;23(10):2631-41 [8405064.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):551-9 [8992967.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1537-46 [9108457.001]
  • [Cites] J Immunol. 1997 Oct 1;159(7):3113-7 [9317107.001]
  • [Cites] Prostate. 1998 Jul 1;36(2):129-38 [9655265.001]
  • [Cites] Immunol Rev. 1999 Aug;170:73-84 [10566143.001]
  • (PMID = 17387370.001).
  • [ISSN] 1523-6161
  • [Journal-full-title] Reviews in urology
  • [ISO-abbreviation] Rev Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1831540
  •  go-up   go-down


21. Haack S, Pedersen EM, Jespersen SN, Kallehauge JF, Lindegaard JC, Tanderup K: Apparent diffusion coefficients in GEC ESTRO target volumes for image guided adaptive brachytherapy of locally advanced cervical cancer. Acta Oncol; 2010 Oct;49(7):978-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent diffusion coefficients in GEC ESTRO target volumes for image guided adaptive brachytherapy of locally advanced cervical cancer.
  • BACKGROUND AND PURPOSE: T2 weighted MRI is recommended for image guided adaptive brachytherapy (IGABT) in cervical cancer.
  • MATERIAL AND METHODS: Fifteen patients with locally advanced cervical cancer were examined by MRI before their first (BT1) and second (BT2) fraction of IGABT, resulting in a total of 30 MR examinations including both T2 weighted and DWI sequences.
  • [MeSH-minor] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / radiotherapy. Diffusion. Disease Progression. Dose Fractionation. Female. Humans. Models, Theoretical. Neoplasm Staging. Organ Size. Radiation Dosage


22. Vickers AJ, Feinstein MB, Deng GE, Cassileth BR: Acupuncture for dyspnea in advanced cancer: a randomized, placebo-controlled pilot trial [ISRCTN89462491]. BMC Palliat Care; 2005 Aug 18;4:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acupuncture for dyspnea in advanced cancer: a randomized, placebo-controlled pilot trial [ISRCTN89462491].
  • BACKGROUND: Dyspnea, or shortness of breath, is a common symptom in patients with advanced cancer.
  • Preliminary data suggest that acupuncture can relieve dyspnea in a variety of populations, including cancer patients.
  • We conducted a pilot study (ISRCTN89462491) preparatory to a fully powered randomized, placebo-controlled trial to determine whether acupuncture reduces dyspnea in patients with lung or breast cancer.
  • METHODS: The study sample was comprised of forty-seven patients with lung or breast cancer presenting with dyspnea.
  • CONCLUSION: The acupuncture technique used in this trial is unlikely to have effects on dyspnea importantly larger than placebo for patients with advanced cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Aug 1;352(9125):364-5 [9717924.001]
  • [Cites] J Cardiopulm Rehabil. 1997 Jul-Aug;17(4):268-76 [9271771.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1511-4 [10643545.001]
  • [Cites] Palliat Med. 1999 Sep;13(5):445 [10659122.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1175-83 [10699909.001]
  • [Cites] Palliat Med. 2000 Jul;14(4):257-65 [10974977.001]
  • [Cites] Eval Health Prof. 2002 Dec;25(4):421-35 [12449085.001]
  • [Cites] Clin J Pain. 1989 Dec;5(4):305-12 [2520420.001]
  • [Cites] Lancet. 1986 Dec 20-27;2(8521-22):1419-22 [2878275.001]
  • [Cites] Ann Allergy. 1977 Dec;39(6):379-87 [339785.001]
  • [Cites] Chest. 1986 Feb;89(2):234-6 [3943383.001]
  • [Cites] Thorax. 1983 Mar;38(3):175-9 [6857580.001]
  • [Cites] Semin Oncol. 1995 Apr;22(2 Suppl 3):67-72 [7537907.001]
  • [Cites] Lancet. 1993 Jul 3;342(8862):13-4 [8100289.001]
  • [Cites] Palliat Med. 1996 Apr;10(2):145-50 [8800822.001]
  • [Cites] Palliat Med. 1999 May;13(3):253-4 [10474714.001]
  • (PMID = 16109163.001).
  • [ISSN] 1472-684X
  • [Journal-full-title] BMC palliative care
  • [ISO-abbreviation] BMC Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1208905
  •  go-up   go-down


23. Al-Tweigeri TA, Ajarim DS, Alsayed AA, Rahal MM, Alshabanah MO, Tulbah AM, Al-Malik OA, Fatani DM, El-Husseiny GA, Elkum NB, Ezzat AA: Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. Med Oncol; 2010 Sep;27(3):571-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
  • The objective of this study is to evaluate the efficacy and safety profile of the doxorubicin followed by cisplatin/docetaxel as primary chemotherapy for patients with locally advanced breast cancer (LABC).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 2):10-4 [11284619.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2676-85 [15837982.001]
  • [Cites] Ann Oncol. 1997 Jul;8(7):663-7 [9296219.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1189-200 [17701939.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jul;98(1):57-61 [16752226.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):56-63 [15598939.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1456-66 [11896092.001]
  • [Cites] Breast Cancer Res Treat. 2000 Aug;62(3):237-44 [11072788.001]
  • [Cites] Br J Surg. 1999 May;86(5):665-8 [10361191.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1005-12 [17047649.001]
  • [Cites] Clin Breast Cancer. 2005 Jun;6(2):163-8 [16001995.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):118S-124S [11560986.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):106S-111S [11560984.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4224-37 [11709566.001]
  • [Cites] Oncology. 2007;72(1-2):17-26 [17998786.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):968-74 [14997191.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1172-6 [17434897.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 3):28-37 [11301372.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):814-9 [18258991.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):286-92 [9888470.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2600-8 [12829681.001]
  • [Cites] Breast Cancer Res Treat. 1995 Apr;34(1):63-9 [7749161.001]
  • [Cites] Ann Oncol. 2004 May;15(5):751-8 [15111342.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):843-50 [12610183.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):778-85 [18258986.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2988-95 [15860854.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4911-6 [17214361.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2012-8 [17513805.001]
  • [Cites] Clin Breast Cancer. 2004 Dec;5(5):371-6 [15585076.001]
  • (PMID = 19526202.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 15H5577CQD / docetaxel; 4G7DS2Q64Y / Progesterone; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Miyagaki H, Fujitani K, Tsujinaka T, Hirao M, Yasui M, Kashiwazaki M, Ikenaga M, Miyazaki M, Mishima H, Nakamori S: The significance of gastrectomy in advanced gastric cancer patients with non-curative factors. Anticancer Res; 2008 Jul-Aug;28(4C):2379-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of gastrectomy in advanced gastric cancer patients with non-curative factors.
  • BACKGROUND: The role of gastrectomy in the treatment of advanced gastric cancer patients with non-curative factors remains controversial.
  • PATIENTS AND METHODS: Eighty-eight advanced gastric cancer patients with non-curative factors were prospectively studied.
  • CONCLUSION: In advanced gastric cancer patients with non-curative factors, gastrectomy was beneficial for survival with longer maintenance of oral intake.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Gastrectomy. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Quality of Life. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751422.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Mercadante S, Villari P, Ferrera P, David F, Intravaia G: High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. J Pain Symptom Manage; 2009 Mar;37(3):419-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients.
  • Peripheral edema is a common feature in populations with advanced cancer, although it is seldom recognized.
  • The aim of this prospective study was to evaluate the efficacy and tolerability of high-dose furosemide and small-volume hypertonic saline solution infusion in reducing leg edema in patients with advanced cancer treated unsuccessfully with diuretics.
  • To be eligible to enter the trial, advanced cancer patients had to have diffuse bilateral leg edema unresponsive to common doses of diuretics.
  • These observations suggest that high-dose furosemide and small-volume saline may be an effective strategy for the treatment of peripheral edema in patients with advanced cancer.

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790601.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diuretics; 0 / Saline Solution, Hypertonic; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


26. Bjurberg M, Kjellén E, Ohlsson T, Bendahl PO, Brun E: Prediction of patient outcome with 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography early during radiotherapy for locally advanced cervical cancer. Int J Gynecol Cancer; 2009 Dec;19(9):1600-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of patient outcome with 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography early during radiotherapy for locally advanced cervical cancer.
  • INTRODUCTION: It is difficult to assess the individual response of locally advanced cervical cancer to chemoradiation therapy during the course of treatment.
  • METHODS: This prospective single-center clinical trial included women with locally advanced cervical cancer from 2004 to 2008.
  • Eleven of the 25 patients with remaining malignant hypermetabolism on the second FDG-PET relapsed.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Disease Progression. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Middle Aged. Positron-Emission Tomography. Prognosis. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955945.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


27. Viola R, Kiteley C, Lloyd NS, Mackay JA, Wilson J, Wong RK, Supportive Care Guidelines Group of the Cancer Care Ontario Program in Evidence-Based Care: The management of dyspnea in cancer patients: a systematic review. Support Care Cancer; 2008 Apr;16(4):329-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of dyspnea in cancer patients: a systematic review.
  • GOALS OF WORK: The goal of the study is to evaluate the effectiveness of four drug classes (opioids, phenothiazines, benzodiazepines, and systemic corticosteroids) for relieving dyspnea experienced by advanced cancer patients.
  • Four reviewers selected evidence using predefined criteria: controlled trials not limited to cancer and involving the specified drug classes for dyspnea treatment.
  • Although the results of individual trials were mixed, the systematic review with meta-analysis detected a significant benefit for dyspnea with systemic opioids; two small placebo-controlled trials in cancer patients found systemic morphine reduced dyspnea, and dihydrocodeine also significantly reduced dyspnea in four placebo-controlled trials.
  • No controlled trials examined systemic corticosteroids in the treatment of cancer patients, and of the other non-opioid drugs examined, only oral promethazine, a phenothiazine, showed some benefit in the relief of dyspnea.
  • CONCLUSIONS: Systemic opioids, administered orally or parenterally, can be used to manage dyspnea in cancer patients.

  • Genetic Alliance. consumer health - Dyspnea.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2002 Nov;57(11):939-44 [12403875.001]
  • [Cites] Am Rev Respir Dis. 1989 Jan;139(1):126-33 [2492170.001]
  • [Cites] Thorax. 1995 Jun;50(6):629-34 [7638804.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1940-5 [8520759.001]
  • [Cites] Chest. 1986 Dec;90(6):832-6 [3780329.001]
  • [Cites] Ann Intern Med. 1993 Nov 1;119(9):906-7 [8215003.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 Feb 26;286(6366):675-7 [6402199.001]
  • [Cites] Q J Med. 1980 Winter;49(193):9-20 [6776586.001]
  • [Cites] Eur Respir J. 1997 May;10(5):1079-83 [9163650.001]
  • [Cites] N Engl J Med. 1981 Dec 31;305(27):1611-6 [6796885.001]
  • [Cites] Thorax. 1996 Jun;51(6):596-600 [8693440.001]
  • [Cites] J Am Coll Cardiol. 1997 Jan;29(1):147-52 [8996307.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):523-8 [12958109.001]
  • [Cites] Semin Oncol. 1995 Apr;22(2 Suppl 3):67-72 [7537907.001]
  • [Cites] J Fam Pract. 1985 Nov;21(5):359-62 [2865326.001]
  • [Cites] Eur Respir J. 1991 Sep;4(8):926-31 [1783082.001]
  • [Cites] Eur J Heart Fail. 2002 Dec;4(6):753-6 [12453546.001]
  • [Cites] Chest. 1993 Jul;104(1):175-8 [8325064.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1511-4 [10643545.001]
  • [Cites] BMC Palliat Care. 2005 Aug 18;4:5 [16109163.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001288 [15674875.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] Chest. 1996 Apr;109(4):975-81 [8635380.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1877-80 [9620921.001]
  • [Cites] Br Med J (Clin Res Ed). 1981 Aug 1;283(6287):343-6 [6788319.001]
  • [Cites] Oncol Nurs Forum. 2004 May;31(3):551-61 [15146221.001]
  • [Cites] J Support Oncol. 2003 May-Jun;1(1):23-32; discussion 32-4 [15352640.001]
  • [Cites] J Pain Symptom Manage. 2006 Jan;31(1):85-95 [16442485.001]
  • [Cites] Eur Respir J. 1997 Oct;10(10):2270-4 [9387952.001]
  • [Cites] J Pain Symptom Manage. 1996 Jul;12(1):3-10 [8718910.001]
  • [Cites] J Pain Symptom Manage. 2005 Jun;29(6):613-8 [15963870.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Jun;16(3):557-77, viii [12170568.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):337-9 [15006905.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(3):CD002872 [12137662.001]
  • [Cites] J Pain Symptom Manage. 1999 Apr;17(4):256-65 [10203878.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):284S-311S [12527586.001]
  • [Cites] J Pain Symptom Manage. 2006 Jan;31(1):38-47 [16442481.001]
  • [Cites] Br J Dis Chest. 1987 Jul;81(3):287-92 [3311120.001]
  • (PMID = 18214551.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Analgesics, Opioid; 0 / Phenothiazines; 12794-10-4 / Benzodiazepines
  • [Number-of-references] 47
  •  go-up   go-down


28. Pasetto LM, D'Andrea MR, Jirillo A, Rossi E, Monfardini S: Stable disease in advanced colorectal cancer: therapeutic implications. Anticancer Res; 2006 Jan-Feb;26(1B):511-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stable disease in advanced colorectal cancer: therapeutic implications.
  • Colorectal cancer is one of the most common neoplasms in Western Countries and ranks second as a cause of death due to cancer.
  • This paper examines the problem related to the treatment of metastatic colorectal cancer with SD.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739312.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 66
  •  go-up   go-down


29. Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, Usari T, Domchek SM: Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res; 2010 Jul 1;16(13):3485-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
  • PURPOSE: Tremelimumab is a fully human monoclonal antibody specific for CTL-associated antigen 4 (CTLA4) with single-agent activity in certain tumors but has not been evaluated in patients with breast cancer.
  • EXPERIMENTAL DESIGN: In a phase 1 study, 26 patients with advanced, hormone-responsive breast cancer received tremelimumab (3-10 mg/kg) every 28 days or every 90 days plus exemestane 25 mg daily.
  • CONCLUSIONS: Tremelimumab plus exemestane is tolerable in patients with hormone-responsive advanced breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. EXEMESTANE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479064.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 107868-30-4 / exemestane; QEN1X95CIX / tremelimumab
  •  go-up   go-down


30. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M: Emerging Raf inhibitors. Expert Opin Emerg Drugs; 2009 Dec;14(4):633-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/METHODS: This review discusses targeting of Raf which could control abnormal proliferation in cancer and other proliferative diseases.
  • Some 'Raf-kinase inhibitors' affect other kinases which are also expressed on malignant cells; yet, these inhibitors have proven useful in the therapy of certain cancer patients.
  • The development of Raf inhibitors has significantly advanced cancer therapy in the past decade.
  • [MeSH-minor] Cell Transformation, Neoplastic. Drug Resistance, Neoplasm. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Humans. MAP Kinase Signaling System / drug effects. Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Protein Kinase Inhibitors / therapeutic use. Signal Transduction / drug effects. Signal Transduction / physiology. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715444.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Grant] United States / PHS HHS / / R01098195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  • [Number-of-references] 95
  •  go-up   go-down


31. Sheng XJ, Zhu YJ, Ye M, Chen JH, Zhang L, Kong L: [Experience in treating advanced prostate cancer with bladder outlet obstruction]. Ai Zheng; 2005 Oct;24(10):1284-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience in treating advanced prostate cancer with bladder outlet obstruction].
  • BACKGROUND & OBJECTIVE: The incidence and discovery rate of prostate cancer is increased in recent years; with advanced age and multiple organs dysfunction, the advanced prostate cancer patients have poor quality of life.
  • METHODS: A total of 80 advanced prostate cancer patients with bladder outlet obstruction were treated by transurethral electrovaporization of the prostate (TVP), plus castration and antiandrogen therapy.
  • CONCLUSION: TVP plus castration and endocrine therapy is a safe and effective treatment for advanced prostate cancer patients with bladder outlet obstruction.
  • [MeSH-minor] Aged. Aged, 80 and over. Androgen Antagonists / therapeutic use. Antigens, Neoplasm / blood. Flutamide / therapeutic use. Humans. Male


32. Schwenke C, Ubrig B, Thürmann P, Eggersmann C, Roth S: Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study. J Urol; 2009 Mar;181(3):1098-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
  • PURPOSE: We investigated the influence of lycopene on the clinical and laboratory course in men with hormone refractory prostate cancer.
  • MATERIAL AND METHODS: We performed a prospective, open phase II pilot study, in which patients with progressive hormone refractory prostate cancer were included.
  • Changes to analgesic use and quality of life (European Organisation for Research and Treatment of Cancer QLQ-C30) were measured.
  • CONCLUSIONS: No clinically relevant benefits were shown for patients with advanced stages of the disease.


33. Copp H, Bissonette EA, Theodorescu D: Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. Urology; 2005 Jun;65(6):1146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
  • Patients with advanced clinically localized prostate cancer have a high likelihood of prostate-specific antigen (PSA) failure 3 to 5 years after initial treatment.
  • Perineural invasion, the percentage of cancer in biopsy cores, pretreatment PSA level, clinical T stage, and Gleason score were analyzed as prognostic factors for biochemical failure defined by both the American Society for Therapeutic Radiology and Oncology (ASTRO) criteria and PSA level greater than 0.2 ng/mL.


34. Navarro Sanz R, López Almazán C: [Approximation to palliative care in the advanced non-malignant diseases]. An Med Interna; 2008 Apr;25(4):187-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Approximation to palliative care in the advanced non-malignant diseases].
  • Nowadays Palliative Medicine (PM) is changing from a specific point of view towards patients with advanced cancer, to another more generic that also keep in mind patients with advanced non malignant disease.
  • But as a matter of fact, these patients with non-cancer diseases unusually go into a Palliative Care (PC) programme.
  • In this article we comment the justification and restriction of PC in patients with non-malignant cancer diseases, as well as the paradoxical situation to come out, in spite of the increasing programes of PC gradually.
  • But above all we propose in a practical way resolve when a patient with non malignant organ advanced disease (NMOAD) could be subsidiary of PC.
  • For that purpose we have to know the diagnosis and the prognostic factors in connection with the EOLCC of the NMOAD more common (advanced chronical pulmonary disease, advanced chronical heart failure, advanced cirrhosis hepatic, advanced chronical renal failure and very evolved dementia), to set up an appropriate make decisions keeping in mind the preferences and wishes of the patient and family, to document and record in the clinical history all those parameters and offerer to the patient the treatment more suitable with the intention to get a worthy death bearing in mind clinical, cultural and ethical standards.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604337.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 44
  •  go-up   go-down


35. Wittekindt C, Sittel C, Kvasnicka HM, Eckel HE: Immunohistochemistry of whole-organ sections of advanced human laryngeal cancer. Eur Arch Otorhinolaryngol; 2006 Aug;263(8):741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry of whole-organ sections of advanced human laryngeal cancer.
  • The aim of this study was to demonstrate the technical aspects of processing horizontal whole-mount sections of advanced laryngeal cancer specimens after total laryngectomy.
  • Those sections may provide new insights in the biology of laryngeal cancer.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / analysis. Antigens, Neoplasm / immunology. DNA Topoisomerases, Type II / analysis. DNA Topoisomerases, Type II / immunology. DNA-Binding Proteins / analysis. DNA-Binding Proteins / immunology. Female. Humans. Ki-67 Antigen / analysis. Ki-67 Antigen / immunology. Larynx / pathology. Larynx / surgery. Male. Tissue Embedding. Treatment Outcome. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / immunology

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trans Am Acad Ophthalmol Otolaryngol. 1950 Sep-Oct;55:10-21 [14788061.001]
  • [Cites] Cancer Res. 1984 Jun;44(6):2259-65 [6372991.001]
  • [Cites] Am J Otolaryngol. 1995 Jan-Feb;16(1):40-8 [7717472.001]
  • [Cites] Laryngoscope. 1977 Apr;87(4 Pt 1):474-82 [839938.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1961 Sep;70:910-21 [13922993.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):613-4 [9389580.001]
  • [Cites] Am J Pathol. 1993 Feb;142(2):381-5 [8434637.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254 Suppl 1:S93-6 [9065638.001]
  • [Cites] Oncogene. 1991 Sep;6(9):1699-703 [1923535.001]
  • [Cites] Laryngoscope. 1996 Sep;106(9 Pt 1):1170-5 [8822725.001]
  • [Cites] Hum Pathol. 1986 Apr;17(4):346-54 [3957335.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] Acta Anat (Basel). 1997;158(1):74-80 [9293301.001]
  • [Cites] Acta Otolaryngol. 1976 Mar-Apr;81(3-4):167-72 [57693.001]
  • [Cites] Adv Otorhinolaryngol. 1984;32:1-123 [6369947.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1989 Sep;98(9):661-7 [2782798.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):820-4 [8795588.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1993 Sep;102(9):660-5 [8373086.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2002;5(3):212-8 [12496984.001]
  • [Cites] Br Med J. 1969 Jun 7;2(5657):615-8 [5798474.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Mar;108(3):232-8 [10086614.001]
  • [Cites] Oral Oncol. 1997 Nov;33(6):408-13 [9509124.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1969 Aug;78(4):689-709 [5799397.001]
  • [Cites] J Pathol. 1992 Oct;168(2):179-85 [1460535.001]
  • (PMID = 16683119.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


36. von Lueder T, Steine K, Nerdrum T, Steen T, Bay D, Humerfelt S, Atar D: Rheumatic mitral valve stenosis mimicking advanced lung cancer. Heart Vessels; 2007 Sep;22(5):345-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rheumatic mitral valve stenosis mimicking advanced lung cancer.
  • This report describes a patient with a perihilar mass and mediastinal lymphadenopathy mimicking advanced lung cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Infect Dis. 2005 Nov;5(11):685-94 [16253886.001]
  • [Cites] Heart Vessels. 2002 Jul;16(5):208-10 [12181597.001]
  • [Cites] Chest. 2001 Feb;119(2):653-6 [11171755.001]
  • [Cites] J Comput Assist Tomogr. 2003 Jul-Aug;27(4):485-9 [12886129.001]
  • [Cites] Chest. 1992 Oct;102(4):1269-71 [1395780.001]
  • (PMID = 17879027.001).
  • [ISSN] 0910-8327
  • [Journal-full-title] Heart and vessels
  • [ISO-abbreviation] Heart Vessels
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G: Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev; 2009;(1):CD006953
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychosocial interventions for reducing fatigue during cancer treatment in adults.
  • BACKGROUND: Fatigue is a common symptom in cancer patients receiving active treatment.
  • There are a limited number of reviews evaluating interventions for fatigue during active treatment, and they are restricted to patients with advanced cancer, or to patients during radiotherapy.
  • To date there is no systematic review on psychosocial interventions for fatigue during cancer treatment.
  • OBJECTIVES: To evaluate if psychosocial interventions are effective in reducing fatigue in cancer patients receiving active treatment for cancer, and which types of psychosocial interventions are the most effective.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) were included which evaluated psychosocial interventions in adult cancer patients during treatment, with fatigue as an outcome measure.
  • AUTHORS' CONCLUSIONS: There is limited evidence that psychosocial interventions during cancer treatment are effective in reducing fatigue.

  • MedlinePlus Health Information. consumer health - Fatigue.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Evid Based Healthc. 2010 Jun;8(2):106-7 [21077401.001]
  • [CommentIn] Aust Occup Ther J. 2010 Apr;57(2):148-9 [20854581.001]
  • (PMID = 19160308.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 127
  •  go-up   go-down


38. Mitchell G, Girgis A, Jiwa M, Sibbritt D, Burridge L: A GP Caregiver Needs Toolkit versus usual care in the management of the needs of caregivers of patients with advanced cancer: a randomized controlled trial. Trials; 2010;11:115
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A GP Caregiver Needs Toolkit versus usual care in the management of the needs of caregivers of patients with advanced cancer: a randomized controlled trial.
  • BACKGROUND: Caring for a person with progressive cancer creates challenges for caregivers.
  • This paper outlines a study protocol aimed at developing and evaluating the effectiveness of a general practice-based intervention to better meet the needs of caregivers of patients with advanced cancer.
  • METHODS/DESIGN: Two hundred and sixty caregivers will be randomised into each of two arms of the intervention (520 participants in total) through patients with advanced cancer attending medical and radiation oncology outpatient clinics at two tertiary hospital sites.
  • DISCUSSION: This study will determine whether systematic assessment of caregiver needs supported by caregiver-specific information for General Practitioners is effective in alleviating the unmet needs experienced by caregivers caring for patients with advanced cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pain Symptom Manage. 1999 Jun;17(6):418-28 [10388247.001]
  • [Cites] J Palliat Med. 2003 Dec;6(6):911-8 [14733683.001]
  • [Cites] Palliat Med. 2005 Oct;19(7):551-5 [16295288.001]
  • [Cites] Eur J Cancer Care (Engl). 2006 May;15(2):163-71 [16643264.001]
  • [Cites] Palliat Med. 2008 Dec;22(8):904-12 [18772208.001]
  • [Cites] Palliat Med. 2008 Dec;22(8):956-64 [18952754.001]
  • [Cites] J Eval Clin Pract. 2009 Aug;15(4):602-6 [19522727.001]
  • [Cites] Psychooncology. 2010 Jul;19(7):726-33 [19777532.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):63-74 [12597468.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):27-39 [12597463.001]
  • [Cites] J Pain Symptom Manage. 2002 Aug;24(2):91-6 [12231124.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Jun;16(3):745-62, xi [12170579.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3219-25 [11432889.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):217-25 [10618626.001]
  • [Cites] Palliat Med. 1994;8(3):183-96 [7952369.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] CMAJ. 2004 Jun 8;170(12):1795-801 [15184333.001]
  • [Cites] J Palliat Med. 2004 Feb;7(1):19-25 [15008126.001]
  • [Cites] Psychooncology. 2011 Apr;20(4):387-93 [20878835.001]
  • [Cites] Med Care. 2003 Aug;41(8):992-1001 [12886178.001]
  • [Cites] Psychooncology. 2005 Jun;14(6):492-502 [15452896.001]
  • (PMID = 21114863.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN43614355
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3009964
  •  go-up   go-down


39. Gérard JP, Ortholan C: [Rectal cancer: which initial strategy?]. Rev Prat; 2010 Oct 20;60(8):1081-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectal cancer: which initial strategy?].
  • [Transliterated title] Cancer du rectum. Quelle stratégie de prise en charge initiale?
  • Advanced T3-4 tumors are treated with pre-operative chemo-radiation often using the "CAP 50" regimen.
  • At the present time, almost 60% of patients are definitively cured of their cancer with 75% being able to avoid permanent stoma.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21197738.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


40. Novak JF, Trnka F: Proenzyme therapy of cancer. Anticancer Res; 2005 Mar-Apr;25(2A):1157-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proenzyme therapy of cancer.
  • However, out of many promising serine and metalloproteinase inhibitors, none are included in cancer treatment regimens at present.
  • The current search for active antiproteolytic compounds is in contrast to the classical approach developed by John Beard, who suggested treating advanced cancer by fresh pancreatic extracts whose antitumor activity was based on their proteolytic potential.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHYMOTRYPSIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2005 May-Jun;25(3c):2599
  • (PMID = 15868959.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Endostatins; 86090-08-6 / Angiostatins; 9002-08-8 / Trypsinogen; 9035-75-0 / Chymotrypsinogen; EC 3.2.1.- / Amylases; EC 3.4.21.1 / Chymotrypsin; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


41. Capirci C, Rubello D, Chierichetti F, Crepaldi G, Fanti S, Mandoliti G, Salviato S, Boni G, Rampin L, Polico C, Mariani G: Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol; 2006 Aug;187(2):W202-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy.
  • OBJECTIVE: The purpose of this study was to assess the prognostic value of (18)F-FDG PET performed at restaging in patients with locally advanced rectal cancer who previously underwent neoadjuvant radiochemotherapy.
  • SUBJECTS AND METHODS: Eighty-eight patients with histologically proven rectal cancer classified at clinical TNM stages II and III were enrolled.
  • CONCLUSION: In patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy, the combined evaluation of pathologic stage and after-radiochemotherapy (18)F-FDG PET at restaging identified a subgroup of patients characterized by good response to radiochemotherapy and a more favorable prognosis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Time Factors

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861513.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


42. de Wilt JH, Vermaas M, Ferenschild FT, Verhoef C: Management of locally advanced primary and recurrent rectal cancer. Clin Colon Rectal Surg; 2007 Aug;20(3):255-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of locally advanced primary and recurrent rectal cancer.
  • Treatment for patients with locally advanced and recurrent rectal cancer differs significantly from patients with rectal cancer restricted to the mesorectum.
  • Much effort should be made to select patients with these advanced tumors for treatment in specialized referral centers.
  • In this article, we review the best treatment options for patients with locally advanced and recurrent rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):668-74 [16446339.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):650-5 [16446336.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):113-9 [16372254.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):105-12 [16302179.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1452-7 [16222445.001]
  • [Cites] Eur J Surg Oncol. 2005 Nov;31(9):1000-5 [16005599.001]
  • [Cites] Radiother Oncol. 2005 Sep;76(3):234-40 [16273666.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1444-8 [16184622.001]
  • [Cites] Eur J Surg Oncol. 2005 Sep;31(7):727-34 [15979271.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2047-53; discussion 2053-4 [15657653.001]
  • [Cites] Cancer Radiother. 2004 Oct;8(5):297-304 [15561595.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):297-308 [10487549.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):886-93; discussion 893-5 [10411435.001]
  • [Cites] Ann Surg Oncol. 1999 Mar;6(2):171-7 [10082043.001]
  • [Cites] Dis Colon Rectum. 1999 Apr;42(4):533-9 [10215058.001]
  • [Cites] Radiology. 1999 Apr;211(1):215-22 [10189474.001]
  • [Cites] Eur J Surg Oncol. 1998 Dec;24(6):528-35 [9870729.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • [Cites] Recent Results Cancer Res. 1998;146:152-60 [9670258.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Ann Surg. 1998 Aug;228(2):194-200 [9712564.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):785-90 [9240647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):777-83 [9240646.001]
  • [Cites] Eur J Surg. 1997 Mar;163(3):199-206 [9085062.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):601-14 [9112459.001]
  • [Cites] Strahlenther Onkol. 1997 Jan;173(1):43-9 [9062588.001]
  • [Cites] Ann Surg Oncol. 1996 Nov;3(6):526-33 [8915483.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):32-5 [8653356.001]
  • [Cites] Arch Surg. 1994 Apr;129(4):390-5; discussion 395-6 [8154965.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):333-9 [12626908.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):583-92 [12409664.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):403-8 [12243814.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1078-84 [12195193.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):49-56 [12125680.001]
  • [Cites] Surgery. 2002 Jul;132(1):27-33 [12110792.001]
  • [Cites] Eur J Surg. 2002;168(1):42-8 [12022371.001]
  • [Cites] Radiother Oncol. 2002 Feb;62(2):201-6 [11937247.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):350-7 [11859207.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):817-25 [11821466.001]
  • [Cites] Surg Oncol Clin N Am. 2005 Jul;14(3):587-606, vii [15978431.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):918-28 [15785886.001]
  • [Cites] Br J Surg. 2005 Jun;92(6):756-63 [15838895.001]
  • [Cites] Recent Results Cancer Res. 2005;165:40-5 [15865019.001]
  • [Cites] Colorectal Dis. 2005 May;7(3):232-40 [15859960.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):104-10 [15827789.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):91-4 [15827784.001]
  • [Cites] Surg Oncol Clin N Am. 2005 Apr;14(2):225-38 [15817236.001]
  • [Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):137-47 [15572096.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):217-24 [15584060.001]
  • [Cites] Br J Surg. 1994 Mar;81(3):452-5 [8173929.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1504-8 [2001537.001]
  • [Cites] Ann Surg. 1987 May;205(5):482-95 [2437869.001]
  • [Cites] Dis Colon Rectum. 1990 Apr;33(4):285-90 [2323277.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3958-64 [15459218.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):219-24 [14728936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):106-12 [14697427.001]
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):27-33 [14699030.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • [Cites] Eur J Surg Oncol. 2003 Nov;29(9):743-6 [14602493.001]
  • [Cites] Am J Surg. 2003 Dec;186(6):660-4 [14672775.001]
  • [Cites] Hepatogastroenterology. 2003 May-Jun;50(51):700-3 [12828064.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):779-85 [12794580.001]
  • [Cites] Dig Surg. 2003;20(3):192-9; discussion 200 [12759498.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):474-80 [12682540.001]
  • [Cites] Ann Surg. 2003 Apr;237(4):502-8 [12677146.001]
  • [Cites] World J Surg. 2001 Dec;25(12):1546-9 [11775189.001]
  • [Cites] Int J Clin Oncol. 2001 Oct;6(5):209-14 [11723741.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1676-81 [11711741.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Surg Oncol. 2000 Dec;9(4):193-204 [11476990.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):806-14 [11391140.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):497-504 [11229667.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):597-604 [11173160.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26 Suppl A:S16-20 [11130874.001]
  • [Cites] Ann Surg Oncol. 2000 Dec;7(10):732-7 [11129420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):843-56 [11020583.001]
  • [Cites] Abdom Imaging. 2000 Sep-Oct;25(5):533-41 [10931993.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):219-26 [10924992.001]
  • [Cites] Eur J Cancer. 2000 May;36(7):868-74 [10785591.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):425-33 [10802370.001]
  • [Cites] Dis Colon Rectum. 2000 Mar;43(3):312-9 [10733111.001]
  • [Cites] J Surg Oncol. 2000 Jan;73(1):47-58 [10649280.001]
  • [Cites] J Am Coll Surg. 2000 Jan;190(1):78-83 [10625236.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2612-24 [10594856.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1438-48 [10566532.001]
  • [Cites] Cancer. 1948 Jul;1(2):177-83 [18875031.001]
  • [Cites] Radiother Oncol. 1995 Mar;34(3):185-94 [7543209.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):939-52 [7531113.001]
  • [Cites] Ann Surg. 1994 Oct;220(4):586-95; discussion 595-7 [7524455.001]
  • [Cites] Semin Oncol. 1993 Oct;20(5):430-45 [8211192.001]
  • [Cites] AJR Am J Roentgenol. 1993 Mar;160(3):525-31 [8430546.001]
  • [Cites] Am J Surg. 1992 Jul;164(1):18-21 [1626601.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):495-501 [1589987.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):843-9 [2016628.001]
  • [Cites] Br J Surg. 2007 Feb;94(2):250 [17256815.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):110-7 [17194912.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):80-7 [17197969.001]
  • [Cites] Dis Colon Rectum. 2006 Nov;49(11):1663-72 [17041749.001]
  • [Cites] Surg Oncol. 2006 Aug;15(2):71-8 [17045800.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1474-81 [17047196.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1257-65 [16912909.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1354-61 [16897330.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):872-8 [16671066.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):529-33 [16705722.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):976-81 [16552435.001]
  • [Cites] Dis Colon Rectum. 2006 Mar;49(3):302-10 [16456638.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39 [16414206.001]
  • [Cites] Clin Radiol. 2006 Mar;61(3):250-8 [16488206.001]
  • (PMID = 20011207.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2789507
  • [Keywords] NOTNLM ; Primary locally advanced rectal cancer / radiotherapy / recurrent rectal cancer / surgery
  •  go-up   go-down


43. Elgqvist J, Ahlberg D, Andersson H, Jensen H, Johansson BR, Kahu H, Olsson M, Lindegren S: Intraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities. World J Oncol; 2010 Jun;1(3):101-110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities.
  • Background: The aim of this study was to investigate the therapeutic efficacy of advanced ovarian cancer in mice, using α-radioimmunotherapy with different high specific activities.
  • Methods: Animals were intraperitoneally inoculated with ≥1 × 10<sup>7</sup> cells of the ovarian cancer cell line NIH:OVCAR-3.
  • Conclusions: Increasing the specific activity indicates a way to enhance the therapeutic outcome of advanced ovarian cancer, regarding macroscopic tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2A):1005-12 [10810388.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8180-5 [16299250.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2806-11 [12231520.001]
  • [Cites] J Nucl Med. 2009 Jul;50(7):1153-60 [19525452.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1228-37 [17145538.001]
  • [Cites] Cancer Immun. 2008 Feb 06;8:3 [18251464.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):571-8 [16446329.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):457-64 [8595159.001]
  • [Cites] J Immunol Methods. 1984 Aug 3;72(1):77-89 [6086763.001]
  • [Cites] Int J Gynecol Cancer. 2003 Sep-Oct;13(5):607-13 [14675343.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):459-62 [10769696.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5379-89 [6604576.001]
  • [Cites] Int J Gynecol Cancer. 2000 Jan;10(S1):44-46 [11240732.001]
  • [Cites] J Oncol. 2010;2010:394913 [19859581.001]
  • [Cites] J Pharm Pharm Sci. 2005 Feb 10;7(4):29-34 [15850546.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):474-80 [1735615.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1342-50 [16883015.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2773-82 [17363599.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):94-101 [9103398.001]
  • [Cites] Cancer Biother Radiopharm. 2000 Feb;15(1):53-64 [10740653.001]
  • [Cites] J Neurocytol. 1981 Feb;10(1):111-31 [7310442.001]
  • [Cites] Nucl Med Biol. 2007 Oct;34(7):779-85 [17921029.001]
  • [Cites] Appl Radiat Isot. 2001 Aug;55(2):157-60 [11393754.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):61-6 [8244176.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):326-31 [17210714.001]
  • [Cites] Cancer Biother Radiopharm. 2009 Aug;24(4):509-13 [19694586.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3249s-3253s [10541371.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):1941-50 [2230887.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):486-94 [9716032.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3914S-21S [14506189.001]
  • [Cites] J Nucl Med. 2005 Mar;46(3):464-71 [15750160.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2710-4 [17354223.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12):2061-7 [16330571.001]
  • [Cites] Acta Oncol. 2000;39(6):741-5 [11130014.001]
  • [Cites] J Nucl Med. 2005 Nov;46(11):1907-15 [16269606.001]
  • [Cites] Cancer Biother Radiopharm. 2001 Aug;16(4):305-15 [11603001.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):691-8 [15196866.001]
  • [Cites] J Nucl Med. 2008 Sep;49(9):1537-45 [18703591.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1A):409-12 [11299770.001]
  • (PMID = 29147189.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; 211At / Alpha / Astatine / Intraperitoneal / Mice / Ovarian cancer / Radioimmunotherapy / Specific activity
  •  go-up   go-down


44. Petrović M, Ilić N, Baskić D: [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer]. Srp Arh Celok Lek; 2010 Jan-Feb;138(1-2):37-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].
  • INTRODUCTION: Non-small cell lung cancer (NSCLC) accounts for about 70-80% of all lung cancers.
  • In comparison with small cell lung cancer, NSCLC has relatively low therapy response.
  • OBJECTIVE: The aim of this study was to determine the influence of neuroendocrine differentiation on treatment response and survival in patients with advanced NSCLC.
  • CONCLUSION: Tissue expression of neuroendocrine markers influences greatly a therapeutic response in patients with advanced stage of NSCLC.


45. Berglund RK, Jones JS, Ulchaker JC, Fergany A, Gill I, Kaouk J, Klein EA: Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology; 2006 Jun;67(6):1253-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis.
  • OBJECTIVES: Locally advanced prostate cancer is frequently treated with radiotherapy and androgen deprivation because of the greater rate of extracapsular disease and the concern that radical prostatectomy (RP) may not be curative in most cases.
  • A case for surgery for locally advanced disease may be made on the basis of a lower rate of local recurrence compared with radiotherapy in our comparative database, data suggesting a survival advantage with pelvic lymph node dissection in those with positive nodes, and the observation of improved survival in those with metastatic disease treated by RP compared with radiotherapy.
  • We report on the feasibility of RP as a primary treatment modality for locally advanced disease.
  • Locally advanced disease was defined as clinical Stage T2b or worse, prostate-specific antigen level greater than 15 ng/mL, and/or a Gleason score of 8 or greater.
  • CONCLUSIONS: RP for locally advanced prostate cancer is feasible, with acute morbidity similar to RP for more localized disease.
  • [MeSH-minor] Feasibility Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Prostate-Specific Antigen / blood. Treatment Failure

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Urol. 2007 Feb;4(2):68-9 [17228312.001]
  • (PMID = 16678888.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


46. Eisenhauer EL, D'Angelica MI, Abu-Rustum NR, Sonoda Y, Jarnagin WR, Barakat RR, Chi DS: Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. Gynecol Oncol; 2006 Dec;103(3):871-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer.
  • Our objective was to determine the incidence and management of effusions that developed after diaphragm surgery in patients with advanced mullerian cancer.
  • METHODS: We reviewed the records of all patients with stage IIIC-IV epithelial ovarian, fallopian tube, or peritoneal cancer who had diaphragm peritonectomy or resection as part of optimal primary cytoreduction at our institution from 2000-2003.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Databases, Factual. Female. Humans. Incidence. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. New York City / epidemiology. Postoperative Complications / epidemiology. Postoperative Complications / etiology. Postoperative Complications / prevention & control. Postoperative Complications / radiography. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16815536.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Narayan K, Fisher RJ, Bernshaw D: Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by magnetic resonance imaging and treated with curative intent. Int J Gynecol Cancer; 2008 May-Jun;18(3):525-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by magnetic resonance imaging and treated with curative intent.
  • Earlier we had shown that tumor volume and corpus invasion were important prognostic factors in cervical cancer and that corpus invasion was associated with nodal metastases.
  • In view of these findings, we wanted to examine the factors associated with the patterns of relapse in cervical cancer patients who were staged by magnetic resonance imaging (MRI) and treated with curative intent.
  • This was a retrospective study of locoregionally advanced cervical cancer patients treated with curative intent.
  • [MeSH-major] Magnetic Resonance Imaging. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging / methods. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / pathology


48. Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JH: Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs; 2005 Oct;23(5):429-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
  • Trabectedin (Yondelis, formerly ET-743) is an anti-cancer drug currently undergoing phase II development.
  • To this aim, we intravenously administered [(14)C]trabectedin to 8 cancer patients, followed by collection of whole blood, urine and faeces samples.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pharmacol Ther. 1967 Jul-Aug;8(4):566-77 [4951973.001]
  • [Cites] Cancer Res. 1958 Apr;18(3):318-28 [13523598.001]
  • [Cites] J Mass Spectrom. 1998 Nov;33(11):1134-40 [9835068.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12 ):6775-9 [10841572.001]
  • [Cites] Arzneimittelforschung. 1967 Nov;17(11):1389-93 [5632152.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1327-31 [15177491.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Nov;12 (11):1843-53 [14585059.001]
  • [Cites] Anticancer Drugs. 2003 Aug;14 (7):487-502 [12960733.001]
  • [Cites] Biochemistry. 1996 Oct 15;35(41):13303-9 [8873596.001]
  • [Cites] Oncologist. 2002;7(6):531-8 [12490740.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14 ):1327-34 [12516966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12 ):6780-4 [10841573.001]
  • [Cites] Anticancer Drugs. 2001 Sep;12 (8):653-66 [11604552.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):75-85 [11801542.001]
  • [Cites] Cancer. 2003 Aug 15;98 (4):832-40 [12910529.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • (PMID = 16133794.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Carbon Radioisotopes; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; ID0YZQ2TCP / trabectedin
  •  go-up   go-down


49. Casaretto L, Sousa PL, Mari JJ: Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Braz J Med Biol Res; 2006 Apr;39(4):431-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis.
  • The aim of the present study was to compare the efficacy of chemotherapy and support treatment in patients with advanced non-resectable gastric cancer in a systematic review and meta-analysis of randomized clinical trials that included a comparison of chemotherapy and support care treatment in patients diagnosed with gastric adenocarcinoma, regardless of their age, gender or place of treatment.
  • 1) randomized clinical trials and antineoplastic combined therapy or gastrointestinal neoplasm, 2) stomach neoplasm and drug therapy, 3) clinical trial and multi-modality therapy, 4) stomach neoplasm and drug therapy or quality of life, 5) double-blind method or clinical trial.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612465.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 27
  •  go-up   go-down


50. Asoglu O, Muslumanoglu M, Igci A, Ozmen V, Karanlik H, Ayalp K, Bozfakioglu Y, Kecer M, Parlak M: Breast conserving surgery after primary chemotherapy in locally advanced breast cancer. Acta Chir Belg; 2005 Feb;105(1):62-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast conserving surgery after primary chemotherapy in locally advanced breast cancer.
  • PURPOSE: Primary chemotherapy is being given in the treatment of locally advanced breast cancers (LABC), but a major concern is local recurrence after therapy.
  • The aim of this study was to assess the role of breast conserving surgery (BCS) in patients with locally advanced breast cancer.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790205.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


51. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH: Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol; 2006 Nov 1;24(31):5025-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
  • PURPOSE: To evaluate the efficacy and toxicity of bortezomib +/- docetaxel as second-line therapy in patients with relapsed or refractory advanced non-small-cell lung cancer (NSCLC).
  • CONCLUSION: Bortezomib has modest single-agent activity in patients with relapsed or refractory advanced NSCLC using this schedule, with minor enhancement in combination with docetaxel.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrazines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075122.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 0 / Taxoids; 15H5577CQD / docetaxel; 69G8BD63PP / Bortezomib
  •  go-up   go-down


52. Katsube T, Ogawa K, Ichikawa W, Fujii M, Tokunaga A, Takagi Y, Kochi M, Hayashi K, Kubota T, Aiba K, Arai K, Terashima M, Kitajima M: Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer. Anticancer Drugs; 2007 Jun;18(5):605-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.
  • A phase I/II study to determine the recommended dose for combination therapy with CPT-11 (irinotecan hydrochloride) and S-1 (tegafur, gimestat and otastat potassium) for advanced or recurrent gastric cancer, and to assess the safety and efficacy of this therapy.
  • This is a well-tolerated ambulatory regimen for advanced gastric cancer.
  • [MeSH-minor] Adult. Aged. Antiemetics / therapeutic use. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Survival Analysis. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414630.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 1548R74NSZ / Tegafur; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


53. Heudel P, Romestaing P, Barbet N, Falandry C, You B, Glehen O, Freyer G: Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial. Clin Oncol (R Coll Radiol); 2008 Jun;20(5):369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
  • AIMS: To determine the feasibility of radiotherapy-associated capecitabine, irinotecan and oxaliplatin administration at five dose levels for the treatment of locally advanced rectal cancer, with or without metastasis.
  • PATIENTS AND METHODS: This was a bicentric phase I trial, including patients with locally advanced rectal cancer, with or without metastasis.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18406583.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


54. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ: Medical treatment of advanced testicular cancer. JAMA; 2008 Feb 13;299(6):672-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical treatment of advanced testicular cancer.
  • CONTEXT: The medical treatment of advanced testicular germ cell tumors has changed over the past 30 years, with long-term survival now achieved in the majority of patients.
  • Clinicians need to be familiar with the available treatment regimens for testicular cancer and their associated toxic effects.
  • OBJECTIVE: To review the treatments used for advanced testicular germ cell tumors and their associated short-term and long-term complications.
  • The Cochrane Register of Controlled Trials Databases (through October 2007) was also searched using the terms testicular cancer or germ cell tumors.
  • One hundred eighty-six articles were selected based on pertinence to advanced testicular cancer treatment, associated complications, and late relapses with an emphasis on randomized controlled trials.
  • DATA SYNTHESIS: The treatment of advanced testicular germ cell tumors with cisplatin combination chemotherapy is based on risk stratification (good, intermediate, or poor prognosis) according to pretreatment clinical features of prognostic value.
  • CONCLUSIONS: Clinical trials have led to evidence-based treatment recommendations for advanced testicular cancer based on risk stratification.

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18270356.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 202
  •  go-up   go-down


55. Couper JW, Love AW, Duchesne GM, Bloch S, Macvean M, Dunai JV, Scealy M, Costello A, Kissane DW: Predictors of psychosocial distress 12 months after diagnosis with early and advanced prostate cancer. Med J Aust; 2010 Sep 6;193(5 Suppl):S58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of psychosocial distress 12 months after diagnosis with early and advanced prostate cancer.
  • OBJECTIVE: To assess psychosocial distress in patients with early (localised) and advanced (metastatic) prostate cancer (PCA) at diagnosis (Time 1) and 12 months later (Time 2), and identify psychosocial factors predictive of later distress.
  • DESIGN, PARTICIPANTS AND SETTING: Observational, prospective study of 367 men with early (211) or advanced (156) PCA recruited as consecutive attendees at clinics at seven public hospitals and practices in metropolitan Melbourne between 1 April 2001 and 30 December 2005.
  • MAIN OUTCOME MEASURES: Health-related quality of life as assessed by the Short Form 36-item Health Survey; psychological distress, including depression and anxiety as assessed by the Brief Symptom Inventory; and coping patterns as assessed by the Mini-Mental Adjustment to Cancer scale.
  • RESULTS: Over the 12 months, both the early and advanced PCA group showed reduced vitality and increased depression and anxiety; this effect was greater in the advanced PCA group.
  • Mental health, social functioning and role-emotional functioning also deteriorated in the advanced group.
  • In the advanced PCA group, depression at Time 2 was predicted by depression and mental health at Time 1; anxiety at Time 2 was predicted by anxiety, mental health, cognitive avoidance and lower anxious preoccupation at Time 1.
  • CONCLUSIONS: Men with early PCA experience decreasing vitality and increasing psychological distress over the 12 months following diagnosis; this trend is accelerated after diagnosis with advanced PCA.
  • A fatalistic coping pattern at diagnosis of early PCA predicts later depression while cognitive avoidance and lower anxious preoccupation at diagnosis of advanced PCA predict later anxiety.
  • [MeSH-minor] Adaptation, Psychological. Adult. Aged. Aged, 80 and over. Australia / epidemiology. Causality. Cohort Studies. Comorbidity. Humans. Male. Middle Aged. Neoplasm Staging. Prevalence. Prospective Studies. Psychiatric Status Rating Scales. Regression Analysis. Severity of Illness Index. Social Support


56. Caponigro F, Facchini G, Nasti G, Iaffaioli RV: Gastric cancer. Treatment of advanced disease and new drugs. Front Biosci; 2005;10:3122-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer. Treatment of advanced disease and new drugs.
  • Gastric cancer is most chemosensitive among gastrointestinal tumors.
  • However, the role of chemotherapy in advanced disease and its advantage over best supportive care has been adequately addressed only in the last decade.
  • The Swiss Group for Clinical Cancer Research has carried out a randomized three-arm phase II study with ECF or docetaxel, cisplatin (TC), or docetaxel, cisplatin, 5-FU (TCF) in advanced gastric cancer.
  • Oxaliplatin is being tested in advanced gastric cancer.
  • Irinotecan is another drug under investigation in advanced gastric cancer, both as single agent and in combination.
  • A randomized phase III study of marimastat versus placebo as maintenance therapy in advanced gastric cancer has shown a significant survival advantage for the marimastat arm, both in the total patient population and in the subgroup of patients who had previously received chemotherapy.
  • Since a clear gold standard for advanced gastric cancer does not yet exist, the inclusion of patients in well designed clinical trials is to be considered the best treatment option.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970566.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydroxamic Acids; 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 7673326042 / irinotecan; D5EQV23TDS / marimastat; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 28
  •  go-up   go-down


57. Alvarez EA, Wolfson AH, Pearson JM, Crisp MP, Mendez LE, Lambrou NC, Lucci JA 3rd: A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer. Gynecol Oncol; 2009 May;113(2):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer.
  • OBJECTIVES: This study was designed to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of weekly docetaxel with concurrent radiotherapy (RT) for the primary treatment of locally advanced squamous cell carcinoma of the cervix.
  • METHODS: Eligible patients included those with locally advanced squamous cell cervical cancer without para-aortic lymph node involvement.
  • CONCLUSIONS: The recommended phase II dose of docetaxel administered weekly with concurrent radiotherapy for locally advanced squamous cell carcinoma of the cervix is 40 mg/m(2).
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Staging


58. Xu N, Shen P, Zhang XC, Yu LF, Bao HY, Shi GM, Huang S, Chen J, Mou HB, Fang WJ: Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol; 2007 Jan;59(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
  • PURPOSE: To evaluate the efficacy and safety of the combination of using gemcitabine as a rate infusion of 10 mg/m(2) per min with carboplatin in front-line chemonaive patients with advanced non-small-cell lung cancer (NSCLC).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614849.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


59. Larsen SG, Wiig JN, Emblemsvaag HL, Grøholt KK, Hole KH, Bentsen A, Dueland S, Vetrhus T, Giercksky KE: Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neo-adjuvant downstaging. Colorectal Dis; 2009 Sep;11(7):759-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neo-adjuvant downstaging.
  • OBJECTIVE: To compare the clinical ability of MRl taken before and after neo-adjuvant treatment in locally advanced rectal cancer (LARC) to predict the necessary extension of TME (ETME) and the possibility to achieve a R0 resection.
  • METHOD: Prospective registration of 92 MRI evaluated T4a cancers undergoing elective surgery between 2002 and 2007 in a tertiary referral centre for multimodal treatment of rectal cancer.
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Fibrosis / complications. Fibrosis / pathology. Humans. Male. Neoplasm Staging / methods. Prospective Studies. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18662240.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Silay MS, Miroglu C: Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects. Med Hypotheses; 2007;69(4):892-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
  • Due to the poor prognosis of advanced bladder carcinoma and the insufficient affects of the chemotherapy agents for this disease, the investigation of the novel genetic and pharmacologic agents including anti-angiogenic agents that can target pathway-specific molecules has been the subject of several publications especially for the last 2 years.
  • Although the clinical trials of these agents are still lacking, the experimental and the preliminary studies are giving hope for the future treatment of advanced bladder carcinoma.
  • According to this knowledge we suggest that these two new agents may also increase the progression-free survival of the patients with advanced bladder carcinoma due to their anti-angiogenic and tumor cell apoptotic effects.
  • We believe that the evaluation of the effects of these agents on bladder cancer population by clinical, prospective and placebo controlled studies may prove our hypothesis and add critical findings to the literature which is still lacking.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17368754.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


61. Lin J, Zhang W, Xie B, Li L, Zhang L, Zheng J, Wang X: [Clinical investigation of IRESSA in the treatment of patients with advanced refractory non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi; 2006 Oct 20;9(5):455-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical investigation of IRESSA in the treatment of patients with advanced refractory non-small cell lung cancer].
  • BACKGROUND: Chemotherapy is a main method for patients with advanced non-small cell lung cancer (NSCLC).
  • NSCLC is usually a drug-resistant neoplasm.
  • To search for a new anti-cancer drug becomes a goal of clinical oncologists.
  • The aim of the present study is to evaluate the curative effect and side reactions of IRESSA in the treatment of patients with advanced refractory NSCLC.
  • METHODS: The curative investigation was carried out after 100-day oral IRESSA by a dosage of 250mg/d in patients with advanced refractory NSCLC.
  • CONCLUSIONS: IRESSA takes better effect on the advanced drug-resistant patients with NSCLC.
  • So IRESSA may be accepted as third line in the treatment of advanced NSCLC and as first line in the treatment of patients with bad constitution who have no opportinities for operation, irradiation therapy or chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176471.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Fanfani F, Fagotti A, Gallotta V, Ercoli A, Pacelli F, Costantini B, Vizzielli G, Margariti PA, Garganese G, Scambia G: Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol Oncol; 2010 Mar;116(3):497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery.
  • OBJECTIVE: Upper abdominal spread of primary and recurrent ovarian cancer is often considered to be a major obstacle to achieve optimal residual disease at the end of surgery.
  • In this study, we investigate the role of diaphragmatic debulking in the natural history of advanced and recurrent epithelial ovarian cancer patients, and the morbidity of this procedure according to clinico-surgical characteristics.
  • METHODS: Data from 234 consecutive patients with primary and recurrent advanced ovarian cancer, operated at Catholic University of Rome and Campobasso from January 1, 2005 and December 31, 2008, were retrospectively reviewed.
  • CONCLUSIONS: Diaphragmatic surgery represents a crucial step in the debulking of advanced and recurrent ovarian cancer patients.
  • Considering the natural history of advanced epithelial ovarian cancer and the rate of patients needing diaphragmatic debulking during primary cytoreduction, interval debulking surgery and secondary cytoreduction, this procedure should be present in the surgical repertoire of a gynecologic oncologist.
  • [MeSH-major] Diaphragm / surgery. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20004958.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Han Y, Xu JM, Duan HQ, Song ST, Liu XQ, Zhang Y, Zhang JS: [EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2007 Apr;29(4):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer].
  • OBJECTIVE: To investigate the correlation between mutation in EGFR tyrosine kinase domain and tumor response as well as prognosis in advanced stage non-small cell lung cancer (NSCLC) treated with iressa.
  • 2005, iressa was orally administered at a dose of 250 mg once daily for 106 advanced stage NSCLC patients until occurrence of disease progression or intolerable toxicity.
  • Cancer tissue was obtained from these patients, and DNA was extracted for analysis of mutation in exon 18 to 24 of EGFR.
  • CONCLUSION: EGFR mutation may be positively correlated with the response and survival in advanced stage Chinese NSCLC patient treated with iressa.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Exons. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Sequence Deletion

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760255.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


64. Mori K, Kobayashi H, Kamiyama Y, Kano Y, Kodama T: A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol; 2009 Jun;64(1):73-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
  • PURPOSE: The efficacy and toxicity of combined paclitaxel (PTX) and gemcitabine (GEM) was evaluated as a protocol for first-line chemotherapy in 40 patients with advanced non-small-cell lung cancer (NSCLC).
  • CONCLUSION: Weekly chemotherapy with PTX plus GEM is effective and is acceptable for the first line treatment of advanced NSCLC.
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Survival Rate. Thrombocytopenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941748.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


65. Sakaguchi Y, Kabashima A, Okita K, Ojima Y, Yamamura S, Nishizaki T, Tashiro H, Matsusaka T: Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer. Gastric Cancer; 2005;8(2):111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer.
  • BACKGROUND: Although combination therapy of S-1 and cisplatin (CDDP) has excellent efficacy against gastric cancer, the effect of the treatment on survival has been unclear.
  • METHODS: Sixty-three patients with advanced or recurrent gastric cancer were treated with S-1, with or without CDDP, as first-line chemotherapy, and the clinical results were compared retrospectively.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864718.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


66. Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM: Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother; 2008 Oct;31(8):781-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our study further demonstrated that our vaccine approach stimulated spontaneous tumor-reactive NY-ESO-1-specific CD8+ T cells in 2 patients with advanced disease, but failed to prime tumor-reactive NY-ESO-1-specific T cells in 1 patient with no spontaneously tumor-induced CD8+ T-cell responses to NY-ESO-1.
  • Collectively, our data support the capability of the analog peptide NY-ESO-1 157-165V in combination with CpG and Montanide to promote the expansion of NY-ESO-1-specific CD8+ T cells in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. D-MANNITOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1998 Jan 19;187(2):265-70 [9432985.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1757-64 [10359579.001]
  • [Cites] J Immunother. 2004 Nov-Dec;27(6):472-7 [15534491.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):739-46 [15696196.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1243-55 [15837811.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):252-7 [15838382.001]
  • [Cites] PLoS Med. 2004 Nov;1(2):e28 [15578105.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1912-6 [16488988.001]
  • [Cites] Annu Rev Immunol. 2006;24:175-208 [16551247.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2326s-2330s [16609053.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):317-27 [16482562.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4112-9 [17371966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52 [17517626.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):2042-8 [17640060.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4499-506 [10969798.001]
  • [Cites] J Immunol. 2000 Jul 15;165(2):948-55 [10878370.001]
  • [Cites] Int Immunol. 1999 Dec;11(12):1971-80 [10590263.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4946-52 [10987311.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):740-5 [11130078.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):766s-772s [11300471.001]
  • [Cites] Annu Rev Immunol. 2002;20:709-60 [11861616.001]
  • [Cites] Nat Med. 2002 Apr;8(4):379-85 [11927944.001]
  • [Cites] J Immunol. 2003 Feb 15;170(4):1822-9 [12574347.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1140-5 [14871849.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Eur J Immunol. 1992 May;22(5):1261-9 [1533591.001]
  • [Cites] J Invest Dermatol. 1996 Jul;107(1):63-7 [8752841.001]
  • [Cites] J Immunol. 1996 Sep 15;157(6):2539-48 [8805655.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1349-54 [9547346.001]
  • (PMID = 18779741.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112198; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCRR NIH HHS / RR / UL1 RR024153; United States / NCI NIH HHS / CA / R01 CA090360; United States / NCI NIH HHS / CA / R01 CA090360-05S1; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCI NIH HHS / CA / R01 CA112198-01; United States / NCI NIH HHS / CA / P50 CA121973; United States / NCI NIH HHS / CA / R01 CA112198-02; United States / NCI NIH HHS / CA / R01 CA090360-04; United States / NCI NIH HHS / CA / R01 CA090360-01A2; United States / NCRR NIH HHS / RR / M01 RR000056-441011; United States / NCI NIH HHS / CA / R01 CA090360-02; United States / NCI NIH HHS / CA / R01 CA112198-04; United States / NCI NIH HHS / CA / R01 CA112198-03; United States / NCI NIH HHS / CA / R01 CA090360-05; United States / NCI NIH HHS / CA / R01 CA090360-03; United States / NCI NIH HHS / CA / CA90360; United States / NCRR NIH HHS / RR / M01 RR000056-36; United States / NCRR NIH HHS / RR / UL1 RR024153-01; United States / NCI NIH HHS / CA / R01 CA112198
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Neoplasm Proteins; 0 / Oleic Acids; 0 / Oligodeoxyribonucleotides; 0 / Peptide Fragments; 0 / ProMune; 0 / peptide NY-ESO-1 157-165; 25339-93-9 / mannide monooleate; 3OWL53L36A / Mannitol
  • [Other-IDs] NLM/ NIHMS84664; NLM/ PMC3901357
  •  go-up   go-down


67. Okajima M, Ikeda S, Egi H, Yoshimitsu M, Asahara T: [Laparoscopic surgery for colonic cancer: present status and evaluation]. Nihon Geka Gakkai Zasshi; 2006 Mar;107(2):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery for colonic cancer: present status and evaluation].
  • It has been 15 years since laparoscopic surgery was first performed in colonic cancer.
  • An inquiry-based analysis by the Japan Society of Endoscopic Surgery (JSES) in 2003 showed a steady increase in the number of laparoscopic colonic resections for cancer.
  • This report also indicates that advanced cancer candidates exceeded early-stage patients in 2003.
  • For colonic qualification, a thorough videotape of colonic cancer resection is to be evaluated so that not only laparoscopic surgical skill but also oncologic handling is taken into account.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613209.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


68. Saba N, Khuri F: The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications. Oncology; 2005;68(1):10-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
  • With recent advances in cancer management, patients with metastatic bone disease are likely to have a prolonged clinical course, with skeletal-related events such as pain, hypercalcemia, pathologic fractures, spinal cord and nerve compression.
  • There is now evidence that newer, highly potent, nitrogen-containing bisphosphonates reduce skeletal complications in patients with bone metastases from other solid tumors (including lung cancer).
  • In this article, we review the different mechanisms of bisphosphonates and the potential role of newer-generation bisphosphonates, such as zoledronic acid, in the management of advanced, metastatic bone disease.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. 1-HYDROXY-1,1-DIPHOSPHONOETHANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15775688.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Diphosphonates; 0 / Imidazoles; 0813BZ6866 / Clodronic Acid; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 114084-78-5 / ibandronic acid; 6PNS59HP4Y / tiludronic acid; 6XC1PAD3KF / zoledronic acid; M2F465ROXU / Etidronic Acid; OYY3447OMC / pamidronate
  • [Number-of-references] 53
  •  go-up   go-down


69. Nishimura R, Tominaga T, Kimura M, Yanagita Y, Tamaki N, Asaishi K, Okamoto Y, Okuyama N, Takeuchi H, Inaba M, Doi T: Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial. Anticancer Drugs; 2008 Oct;19(9):911-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
  • We conducted a phase II study to determine the availability and safety of combination chemotherapy with weekly paclitaxel and doxifluridine (a capecitabine metabolite) in the treatment of advanced or recurrent breast cancer.
  • The good response rate and long time to progression and overall survival time of this doxifluridine combined with weekly paclitaxel therapy indicate its potential as a first-line or second-line treatment for advanced or recurrent breast cancer patients.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766005.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


70. Nowak M, Klink M, Glowacka E, Sulowska Z, Kulig A, Szpakowski M, Szyllo K, Tchorzewski H: Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells. Scand J Immunol; 2010 Feb;71(2):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells.
  • We investigated an ability of peripheral blood mononuclear cells (PBMC) of patients with early and advanced stages of ovarian cancer and from non-cancer patients to produce various cytokines in the presence or absence of autologous ovarian cancer (OC) cells or benign ovarian tumour (BOT) cells.
  • Activated PBMC of patients with advanced stage of cancer produced slight amount of interferon gamma (IFN-gamma) and what's more, the production of IFN-gamma was decreased in the presence of OC cells.
  • PBMC of patients with ovarian cancer or benign ovarian tumour generated comparable amounts of interleukin 6 and 10 (IL-6, IL-10), and transforming growth factor beta1 (TGF-beta1).
  • PBMC of the patients with cancer produced higher amount of tumour necrosis factor alpha (TNF-alpha) than PBMC of non-cancer patients.
  • We demonstrated here that the reciprocal contact of OC cells from advanced cancer with autologous PBMC altered the direction of produced cytokines and leads to the down-regulation of IFN-gamma and TNF-alpha as well as to up-regulation of immunosuppressive (IL-10, TGF-beta1) and pro-inflammatory (IL-6) cytokines production.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20384860.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


71. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, Badwe R: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol; 2010 Mar 10;28(8):1301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
  • The efficacy and safety of neratinib were evaluated in two cohorts of patients with advanced ErbB2-positive breast cancer-those with and those without prior trastuzumab treatment-in an open-label, multicenter, phase II trial.
  • CONCLUSION: Oral neratinib showed substantial clinical activity and was reasonably well tolerated among both heavily pretreated and trastuzumab-naïve patients who had advanced, ErbB2-positive breast cancer.


72. Chen YC, Pu YS, Wu HC, Wu TT, Lai MK, Yang CY, Sung FC: Cadmium burden and the risk and phenotype of prostate cancer. BMC Cancer; 2009;9:429
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cadmium burden and the risk and phenotype of prostate cancer.
  • BACKGROUND: Studies on the association between prostate cancer and cadmium exposure have yielded conflicting results.
  • This study explored cadmium burden on the risk and phenotype of prostate cancer in men with no evident environmental exposure.
  • METHODS: Hospital-based 261 prostate cancer cases and 267 controls with benign diseases were recruited from four hospitals in Taiwan.
  • Statistical analyses measured the prostate cancer risk associated with BCd and CAUCd separately, controlling for age, smoking and institution.
  • However, cases with higher BCd and CAUCd levels tended to be at more advanced stages and to have higher Gleason scores.
  • The prostate cancer cases with Gleason scores of > or = 8 had an odds ratio of 2.89 (95% confidence interval 1.25-6.70), compared with patients with scores of 2-6.
  • CONCLUSION: Higher CAUCd and BCd levels may be associated with advanced cancer phenotypes, but there was only a tenuous association between cadmium and prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1977 Sep 10;2(8037):566-7 [95781.001]
  • [Cites] Prostate. 2008 Feb 1;68(2):122-8 [18044729.001]
  • [Cites] J Natl Cancer Inst. 1993 Oct 6;85(19):1571-9 [8105097.001]
  • [Cites] Clin Chem. 1994 Jul;40(7 Pt 2):1391-4 [8013125.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):652-61 [7752270.001]
  • [Cites] Am J Epidemiol. 1996 Feb 15;143(4):363-73 [8633620.001]
  • [Cites] Am J Ind Med. 1997 May;31(5):645-52 [9099369.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):484-91 [10430257.001]
  • [Cites] Ann Occup Hyg. 1965 Mar;8:55-61 [14287870.001]
  • [Cites] Cancer Invest. 2005;23(3):256-63 [15945511.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1057-61 [16205693.001]
  • [Cites] Int J Androl. 2000;23 Suppl 2:34-6 [10849490.001]
  • [Cites] Environ Res. 1981 Oct;26(1):217-40 [7028475.001]
  • [Cites] Am J Ind Med. 1980;1(3-4):307-17 [7044111.001]
  • [Cites] Can J Public Health. 1982 Mar-Apr;73(2):92-4 [7104934.001]
  • [Cites] J Anal Toxicol. 1982 May-Jun;6(3):135-8 [7109556.001]
  • [Cites] Urol Res. 1982;10(6):301-3 [6186062.001]
  • [Cites] Environ Health Perspect. 1984 Mar;54:147-52 [6376088.001]
  • [Cites] Urol Res. 1984;12(2):147-50 [6204433.001]
  • [Cites] Br J Ind Med. 1985 Aug;42(8):540-5 [4016005.001]
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4656-63 [3396014.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1388-92 [2465818.001]
  • [Cites] Nephron. 1989;52(1):45-54 [2565539.001]
  • [Cites] Sci Total Environ. 1992 May 15;116(3):243-51 [1615308.001]
  • [Cites] Crit Rev Toxicol. 1992;22(3-4):175-201 [1388705.001]
  • [Cites] Sci Total Environ. 2007 Feb 1;373(1):77-81 [17175009.001]
  • [Cites] IARC Sci Publ. 1992;(118):301-10 [1303956.001]
  • (PMID = 20003241.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 00BH33GNGH / Cadmium
  • [Other-IDs] NLM/ PMC2797022
  •  go-up   go-down


73. Ohba T, Yamasaki T, Endo Y, Furuie M, Ohtani Y, Inase N, Yoshizawa Y: A phase I study of TS-1 plus carboplatin in patients with advanced non-small-cell lung cancer. J Chemother; 2009 Feb;21(1):80-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of TS-1 plus carboplatin in patients with advanced non-small-cell lung cancer.
  • A phase i study of tS-1 plus carboplatin combination therapy was conducted to determine the maximum tolerated dose (MTD), recommended dose (RD), and dose limiting toxicities (DLT) in advanced non-small-cell lung cancer (NSClC).
  • Fifteen patients with advanced NSClC were analyzed. the grade 3-4 toxicities observed during the first cycle were febrile neutropenia (6%), anemia (6%), anorexia (6%), and diarrhea (6%).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19297278.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; BG3F62OND5 / Carboplatin
  •  go-up   go-down


74. Gil-Moreno A, Maffuz A, Díaz-Feijoo B, Puig O, Martínez-Palones JM, Pérez A, García A, Xercavins J: Modified approach for extraperitoneal laparoscopic staging for locally advanced cervical cancer. J Exp Clin Cancer Res; 2007 Dec;26(4):451-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified approach for extraperitoneal laparoscopic staging for locally advanced cervical cancer.
  • Describe a modified approach to the technique for staging laparoscopic extraperitoneal aortic and common iliac lymph node dissection for locally advanced cervical cancer.Retrospective, nonrandomized clinical study. (Canadian Task Force classification II-2), setting in an acute-care, teaching hospital.
  • Thirty-six patients with locally advanced cervical cancer underwent laparoscopic surgical staging via extraperitoneal approach with the conventional or the modified technique from August 2001 through September 2004.
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome


75. Schallier D, Neyns B, Fontaine C, Steene JV, De Mey J, Meysman M, De Grève J: A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC). Lung Cancer; 2007 May;56(2):247-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
  • Phase II study of 3 cycles of triplet induction chemotherapy (response, toxicity) followed by radiotherapy in locally advanced non small cell lung cancer (NSCLC).
  • BACKGROUND: Patients with locally advanced inoperable non-small cell lung cancer are currently treated with concomitant or sequential chemotherapy and radiotherapy.
  • OBJECTIVE: To study the antitumour activity and toxicity of a triplet combination of paclitaxel, carboplatin and gemcitabine as induction chemotherapy before radiotherapy, in locally advanced NSCLC and to evaluate time to progression and survival.
  • CONCLUSION: Three cycles of the novel triplet combination of paclitaxel, carboplatin and gemcitabine (PACCAGE) is an active and feasible induction regimen for patients with locally advanced inoperable NSCLC.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337086.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


76. Bonetti A, Zaninelli M, Durante E, Fraccon AP, Franceschi T, Pasini F, Zustovich F, Brienza S: Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy evaluation. A phase I-II study. Tumori; 2006 Sep-Oct;92(5):389-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy evaluation. A phase I-II study.
  • AIMS AND BACKGROUND: To identify the maximum tolerated doses and to define the activity of a regimen incorporating leucovorin (LV)-modulated 5-fluorouracil (5-FU) bolus and continuous infusion, oxaliplatin (I-OHP) and irinotecan (CPT-11) in patients with advanced, 5-FU-refractory colorectal cancer (CRC).
  • CONCLUSIONS: This study confirms the feasibility of triplet chemotherapy in patients with advanced 5-FU-refractory CRC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Drug Resistance, Neoplasm. Fluorouracil / therapeutic use
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Disease-Free Survival. Drug Administration Schedule. Feasibility Studies. Female. Humans. Infusions, Intravenous. Injections, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168430.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


77. Dy SM, Lorenz KA, Naeim A, Sanati H, Walling A, Asch SM: Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol; 2008 Aug 10;26(23):3886-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea.
  • PURPOSE The experience of patients with cancer often involves symptoms of fatigue, anorexia, depression, and dyspnea.
  • Results For fatigue, providers should screen patients at the initial visit, for newly identified advanced cancer, and at chemotherapy visits; assess for depression and insomnia in newly identified fatigue; and follow up after treatment for fatigue or a secondary cause.
  • For anorexia, providers should screen at the initial visit for cancer affecting the oropharynx or gastrointestinal tract or advanced cancer, evaluate for associated symptoms, treat underlying causes, provide nutritional counseling for patients undergoing treatment that may affect nutritional intake, and follow up patients given appetite stimulants.
  • For depression, providers should screen newly diagnosed patients, those started on chemotherapy or radiotherapy, those with newly identified advanced disease, and those expressing a desire for hastened death; document a treatment plan in diagnosed patients; and follow up response after treatment.
  • For general dyspnea, providers should evaluate for causes of new or worsening dyspnea, treat or symptomatically manage underlying causes, follow up to evaluate treatment effectiveness, and offer opioids in advanced cancer when other treatments are unsuccessful.
  • For dyspnea and malignant pleural effusions, providers should offer thoracentesis, follow up after thoracentesis, and offer pleurodesis or a drainage procedure for patients with reaccumulation and dyspnea.
  • CONCLUSION These standards provide a framework for evidence-based screening, assessment, treatment, and follow-up for cancer-associated symptoms.


78. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E: Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res; 2008 Apr 15;14(8):2431-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
  • PURPOSE: Nephrectomy before immunotherapy in patients with metastatic renal cell cancer (RCC) will improve patient outcome.
  • Sunitinib is now approved for treatment of advanced RCC, but its effect on the primary tumor has yet to be reported.
  • EXPERIMENTAL DESIGN: All patients treated with sunitinib for advanced RCC without prior nephrectomy were reviewed and sequential computed tomography scans were evaluated for response in the primary tumor as well as metastases according to Response Evaluation Criteria in Solid Tumors.
  • Further trials need to address the role of nephrectomy in advanced RCC patients on sunitinib treatment.

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413834.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


79. Wehler T, Wolfert F, Schimanski CC, Gockel I, Herr W, Biesterfeld S, Seifert JK, Adwan H, Berger MR, Junginger T, Galle PR, Moehler M: Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol Rep; 2006 Dec;16(6):1159-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease.
  • The aim of this study was to evaluate if the expression of CXCR4 influences progression of human pancreatic cancer.
  • CXCR4 expression of pancreatic cancer was retrospectively assessed by immunohistochemistry in 103 patients with pancreatic cancer.
  • Human pancreatic cancer revealed variable intensities of CXCR4 expression.
  • Strong CXCR4 expression was significantly associated with advanced UICC stages (P=0.03) and revealed a trend for hematogenous metastasis (P=0.09) and progressed local tumor stages (P=0.15).
  • In summary, strong expression of CXCR4 was significantly associated with advanced pancreatic cancer.
  • [MeSH-minor] Aged. Biomarkers, Tumor. Blotting, Western. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089032.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, CXCR4
  •  go-up   go-down


80. Dy SM, Apostol CC: Evidence-based approaches to other symptoms in advanced cancer. Cancer J; 2010 Sep-Oct;16(5):507-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based approaches to other symptoms in advanced cancer.
  • Dyspnea, nausea and vomiting, anorexia, fatigue, and sleep disturbances are common and distressing in advanced cancer.
  • The strongest evidence supports metoclopramide for cancer-related nausea and octreotide for bowel obstruction.
  • For insomnia, evidence supports cognitive-behavioral therapy in cancer; no sleep agents have superior effectiveness.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890148.001).
  • [ISSN] 1540-336X
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


81. Lou F, Zhu YH, Pan HM: [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Jan;31(1):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
  • OBJECTIVE: To evaluate the efficacy and safety of the combination of oxaliplatin and ELF (VP16/CF/5-Fu) regimen in the treatment of patients with advanced gastric cancer.
  • All cases were pathologically confirmed as gastric cancer (adenocarcinoma in 57 cases and signet ring cell carcinoma in 12 cases).
  • CONCLUSION: This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients.
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Leucovorin / adverse effects. Leucovorin / therapeutic use. Leukopenia / chemically induced. Levoleucovorin. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Vomiting / chemically induced

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538878.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 6PLQ3CP4P3 / Etoposide; 990S25980Y / Levoleucovorin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; ELF protocol
  •  go-up   go-down


82. Costantini A, Baile WF, Lenzi R, Costantini M, Ziparo V, Marchetti P, Grassi L: Overcoming cultural barriers to giving bad news: feasibility of training to promote truth-telling to cancer patients. J Cancer Educ; 2009;24(3):180-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overcoming cultural barriers to giving bad news: feasibility of training to promote truth-telling to cancer patients.
  • BACKGROUND: In many countries, physicians are reluctant to disclose unfavorable medical information to patients with advanced cancer and instead give the bad news to the family.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1999 Sep;10(9):1095-100 [10572608.001]
  • [Cites] Med Educ. 1999 Sep;33(9):655-68 [10476016.001]
  • [Cites] J Pain Symptom Manage. 1999 Jun;17(6):402-9 [10388245.001]
  • [Cites] Soc Sci Med. 1997 May;44(10):1433-52 [9160435.001]
  • [Cites] Support Care Cancer. 2004 Mar;12(3):147-54 [15074312.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):765-9 [11821459.001]
  • [Cites] Acad Med. 2006 Jul;81(7):638-44 [16799286.001]
  • [Cites] Ann Oncol. 2006 May;17(5):853-9 [16551764.001]
  • [Cites] Oncologist. 2000;5(4):302-11 [10964998.001]
  • [Cites] Palliat Med. 2001 Sep;15(5):372-8 [11591088.001]
  • [Cites] Support Care Cancer. 2004 Mar;12(3):143-6 [14727171.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Dec;52(3):165-72 [15582784.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3141-9 [12915605.001]
  • [Cites] Recent Results Cancer Res. 2006;168:105-12 [17073196.001]
  • [Cites] J Cancer Educ. 2005 Summer;20(2):79-84 [16083370.001]
  • [Cites] J Cancer Educ. 2003 Winter;18(4):194-201 [14766329.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2189-96 [11956281.001]
  • [Cites] JAMA. 2008 Jun 11;299(22):2667-78 [18544726.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2433-6 [12805343.001]
  • [Cites] Arch Intern Med. 2007 Mar 12;167(5):453-60 [17353492.001]
  • [Cites] Support Care Cancer. 2000 Jan;8(1):40-5 [10650896.001]
  • (PMID = 19526404.001).
  • [ISSN] 1543-0154
  • [Journal-full-title] Journal of cancer education : the official journal of the American Association for Cancer Education
  • [ISO-abbreviation] J Cancer Educ
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


83. Seto M, Inoue D, Sakuyama T, Arakawa Y, Ichiba T, Aiba K: [A case of an advanced pancreatic cancer (stage IVb) outpatient who could not maintain a home-based care until her death]. Gan To Kagaku Ryoho; 2008 Dec;35 Suppl 1:10-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of an advanced pancreatic cancer (stage IVb) outpatient who could not maintain a home-based care until her death].
  • The number of cancer patients and their families desiring home-based care has been increasing over the last few years.
  • We reported a patient, a 40-year old female patient with advanced pancreatic cancer (T4N3M1, Stage IVb).
  • [MeSH-minor] Adult. Ambulatory Care. Analgesics, Opioid / administration & dosage. Analgesics, Opioid / therapeutic use. Fatal Outcome. Female. Humans. Neoplasm Staging. Pain / drug therapy. Palliative Care. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Home Care Services.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20443291.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


84. Dimova I, Yosifova A, Zaharieva B, Raitcheva S, Doganov N, Toncheva D: Association of 20q13.2 copy number changes with the advanced stage of ovarian cancer-tissue microarray analysis. Eur J Obstet Gynecol Reprod Biol; 2005 Jan 10;118(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of 20q13.2 copy number changes with the advanced stage of ovarian cancer-tissue microarray analysis.
  • In order to study the relation of the increased copy number of 20q13.2 with tumor phenotype in ovarian cancer, we applied FISH on a tissue microarray.
  • Overall, the frequency of 20q13.2 alterations in epithelial ovarian cancer was 25.50% (10.74% gains and 14.76% amplifications).
  • Our results showed strong association between increases 20q13.2 copies and advanced tumor stage.
  • We concluded that genetic alterations in 20q13.2 may be of prognostic significance for stage progression of the ovarian cancer.
  • [MeSH-minor] Female. Humans. In Situ Hybridization, Fluorescence. Microarray Analysis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15596278.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


85. Wang J, Zhang Q, Zhang H, Wang Q, Yang X, Gu Y, Zhang S: [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy]. Zhongguo Fei Ai Za Zhi; 2010 Apr;13(4):337-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy].
  • BACKGROUND AND OBJECTIVE: Results of studies on genetic polymorphisms of ERCC1 gene in DNA repair pathway which may affect response to platinum-based chemotherapy and survival in patients with non-small cell lung cancer are conflicting.
  • The aim of this study is to prospectively assess the association between single nucleotide polymorphisms of C8092A and codon118 in ERCC1 and drug response in 90 patients with advanced non-small cell lung cancer treated with cisplatin-based chemotherapy.
  • CONCLUSION: The results suggest that there is no association between polymorphisms in ERCC1 C8092A and codon118 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy.


86. Shin YM, Han HS, Lim SW, Kim BC, Cheoi KS, Eum YO, Kim ST, Lee KH: Combination chemotherapy of oxaliplatin, 5-fluorouracil and low dose leucovorin in patients with advanced colorectal cancer. Cancer Res Treat; 2005 Oct;37(5):284-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy of oxaliplatin, 5-fluorouracil and low dose leucovorin in patients with advanced colorectal cancer.
  • PURPOSE: The aim of this study was to evaluate the efficacy and tolerability of the oxaliplatin, 5-fluorouracil (5-FU) and low dose leucovorin (LV) combination in patients with advanced colorectal cancer.
  • CONCLUSION: The combination chemotherapy of oxaliplatin, low dose LV and continuous infusion of 5-FU is safe and has a cost-benefit, but is a moderately effective regimen in advanced colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):14-20 [7677801.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):476-87 [15689586.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2739-44 [9704726.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):105-8 [9541691.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):368-81 [8996164.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3766-75 [15365073.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):1000-5 [11334725.001]
  • [Cites] J Korean Med Sci. 2001 Feb;16(1):69-74 [11289404.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001545 [10796809.001]
  • [Cites] Lancet. 2000 May 6;355(9215):1588-96 [10821362.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5970-6 [8261411.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1280-4 [8343268.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):832-7 [15756253.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1303-11 [7751875.001]
  • [Cites] Biomed Pharmacother. 1989;43(4):237-50 [2675999.001]
  • (PMID = 19956528.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2785929
  • [Keywords] NOTNLM ; 5-Fluorouracil / Colorectal neoplasm / Leucovorin / Oxaliplatin
  •  go-up   go-down


87. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A, GERCOR, GISCAD: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol; 2005 May 20;23(15):3509-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
  • PURPOSE: Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer.
  • Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer.
  • PATIENTS AND METHODS: Patients with advanced pancreatic cancer were stratified according to center, performance status, and type of disease (locally advanced v metastatic) and randomly assigned to either GemOx (gemcitabine 1 g/m2 as a 100-minute infusion on day 1 and oxaliplatin 100 mg/m2 as a 2-hour infusion on day 2 every 2 weeks) or Gem (gemcitabine 1 g/m2 as a weekly 30-minute infusion).
  • GemOx was well tolerated overall, although a higher incidence of National Cancer Institute Common Toxicity Criteria grade 3 and 4 toxicity per patient was observed for platelets (14.0% for GemOx v 3.2% for Gem), vomiting (8.9% for GemOx v 3.2% for Gem), and neurosensory symptoms (19.1% for GemOx v 0% for Gem).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Deoxycytidine / analogs & derivatives. Neoplasm Invasiveness / pathology. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Confidence Intervals. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Probability. Proportional Hazards Models. Reference Values. Risk Assessment. Survival Analysis. Treatment Outcome


88. Egawa T, Ohashi M, Ito Y, Hayashi S, Doi M, Nagashima A: [A partial response to combined S-1 and CDDP chemotherapy enabling a curative resection in a patient with locally advanced duodenal cancer]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2083-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A partial response to combined S-1 and CDDP chemotherapy enabling a curative resection in a patient with locally advanced duodenal cancer].
  • Six months after the operation, the patient was doing well and showed no signs of recurrence of the cancer.
  • This S-1/CDDP combination chemotherapy was therefore considered to be suitable as neo-adjuvant chemotherapy because it permitted the patient to subsequently undergo a curative resection, and thereby achieving a survival benefit for locally advanced duodenal cancer.
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Combinations. Duodenoscopy. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106531.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


89. Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N: Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn; 2010 Nov;10(8):1051-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
  • The prognostic and/or predictive value of the cancer biomarkers, urokinase-type plasminogen activator (uPA) and its inhibitor (plasminogen activator inhibitor [PAI]-1), determined by ELISA in tumor-tissue extracts, was demonstrated for several cancer types in numerous clinically relevant retrospective or prospective studies, including a multicenter breast cancer therapy trial (Chemo-N0).
  • Consequently, for the first time ever for any cancer biomarker for breast cancer, uPA and PAI-1 have reached the highest level of evidence, level-of-evidence-1.
  • At present, two other breast cancer therapy trials, NNBC-3 and Plan B, also incorporating uPA and PAI-1 as treatment-assignment tools are in effect.
  • Furthermore, small synthetic molecules targeting uPA are currently in Phase II clinical trials in patients afflicted with advanced cancer of the ovary, breast or pancreas.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21080821.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oligonucleotides, Antisense; 0 / Plasminogen Activator Inhibitor 1; 0 / RNA, Small Interfering; 0 / Serine Proteinase Inhibitors; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


90. Yonenaga Y, Mori A, Fujimoto A, Nagayama S, Tachibana T, Onodera H, Uemoto S: The administration of naked plasmid DNA into the liver induces antitumor innate immunity in a murine liver metastasis model. J Gene Med; 2007 Apr;9(4):299-307
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gene therapy is a promising strategy against advanced cancer; however, the safety of viral vectors and the effectiveness of non-viral vectors have not yet been established.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytotoxicity Tests, Immunologic. Genetic Vectors / genetics. Genetic Vectors / metabolism. Humans. Interferon-gamma / immunology. Killer Cells, Natural / immunology. Leukocytes, Mononuclear / immunology. Male. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 John Wiley & Sons, Ltd.
  • (PMID = 17397091.001).
  • [ISSN] 1099-498X
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 82115-62-6 / Interferon-gamma; 9007-49-2 / DNA
  •  go-up   go-down


91. Pal SK, Twardowski P, Sartor O: Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging; 2010 Dec 03;5:395-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
  • Docetaxel remains a cornerstone of therapy for the patient with metastatic castration-resistant prostate cancer (CRPC).
  • Subsequent to phase I testing in advanced solid tumors (where neutropenia was identified as a dose-limiting toxicity), the agent was assessed in a phase II trial in advanced, taxane-refractory breast cancer and in the aforementioned phase III TROPIC study.
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Drug Resistance, Neoplasm. Female. Humans. Male. Mice. Neutropenia / chemically induced. Prednisone / therapeutic use. Rats

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. PREDNISONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Biochem. 1982 Oct;127(2):319-24 [6128228.001]
  • [Cites] Blood. 1982 Aug;60(2):474-83 [6124288.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1566-72 [7687666.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2928-38 [9256137.001]
  • [Cites] Front Biosci. 2007;12:4957-71 [17569623.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 1):844-8; discussion 848 [17631339.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1255-60 [18381372.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1547-52 [18436520.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10):1749-53 [18487550.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4563-71 [18645193.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):723-30 [19147780.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Aug;18(8):1183-9 [19604119.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3742-8 [19470933.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Dec;65(1):129-36 [19437020.001]
  • [Cites] Clin Cancer Res. 2010 Jan 1;16(1):203-11 [20008841.001]
  • [Cites] Lancet. 2010 Apr 24;375(9724):1437-46 [20398925.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jul;122(2):409-18 [20454927.001]
  • [Cites] J Urol. 2010 Aug;184(2):512-8 [20620410.001]
  • [Cites] N Engl J Med. 2010 Jul 29;363(5):411-22 [20818862.001]
  • [Cites] N Engl J Med. 2010 Jul 29;363(5):479-81 [20818868.001]
  • [Cites] Lancet. 2010 Oct 2;376(9747):1147-54 [20888992.001]
  • [Cites] J Clin Oncol. 2012 May 1;30(13):1534-40 [22454414.001]
  • [Cites] J Urol. 2002 Jul;168(1):9-12 [12050481.001]
  • [Cites] Br J Pharmacol. 2003 Apr;138(7):1367-75 [12711638.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] J Biol Chem. 1981 Oct 25;256(20):10435-41 [6116707.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):414-24 [2936872.001]
  • (PMID = 21152241.001).
  • [ISSN] 1178-1998
  • [Journal-full-title] Clinical interventions in aging
  • [ISO-abbreviation] Clin Interv Aging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K12 CA001727; United States / NCI NIH HHS / CA / K12 2K12CA001727-16A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; 51F690397J / cabazitaxel; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC2998247
  • [Keywords] NOTNLM ; Jevtana / breast cancer / cabazitaxel / castration resistant prostate cancer / taxane
  •  go-up   go-down


92. Meyer A, Behrend M: Pancreatic head resection for invasive colon cancer--apropos of a case. Anticancer Res; 2007 May-Jun;27(3B):1733-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic head resection for invasive colon cancer--apropos of a case.
  • BACKGROUND: Despite the possibilities for early detection of colon cancer, some patients present with locally advanced cancer with invasion of adjacent organs.
  • A case of right colonic cancer with infiltration of the duodenum and pancreas that was treated with hemicolectomy and duodeno-pancreatectomy (DP) en bloc is reported.
  • Clinical examination, including upper and lower intestinoscopy and computed tomography of the abdomen, revealed right-sided colonic cancer with infiltration of the duodenum and the pancreas causing a bleeding duodenal ulcer that was the origin of the anaemia.
  • The primary colon cancer seemed to be resectable without suspicion of hepatic metastases or peritoneal seeding, and a right-sided hemicolectomy with en bloc duodeno-pancreatectomy was carried out.
  • CONCLUSION: This case demonstrates that even common diseases such as colonic cancer may require a careful preoperative diagnosis so that a patient with a locally advanced tumour may be transferred to a specialist centre.
  • [MeSH-minor] Aged. Duodenal Neoplasms / secondary. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595806.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 40
  •  go-up   go-down


93. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, Worden FP: A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid; 2010 Sep;20(9):975-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.
  • BACKGROUND: Currently, there is no standard treatment for metastatic anaplastic thyroid cancer (ATC).
  • DNA microarray analysis has shown platelet-dervived growth factor receptor (PDGFR) overexpression in ATC relative to well-differentiated thyroid cancer.
  • CONCLUSIONS: Imatinib appears to have activity in advanced ATC and is well tolerated.


94. Lesinski GB, Zimmerer JM, Kreiner M, Trefry J, Bill MA, Young GS, Becknell B, Carson WE 3rd: Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer; 2010 Apr 14;10:142
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Endogenously produced interferons can regulate the growth of melanoma cells and are administered exogenously as therapeutic agents to patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):720-5 [10699955.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2859-67 [10561363.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2444-58 [10856105.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21596-604 [10764816.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1251-62 [11850845.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2504-12 [11971185.001]
  • [Cites] J Interferon Cytokine Res. 2002 May;22(5):603-13 [12060499.001]
  • [Cites] Nat Rev Immunol. 2002 Jun;2(6):410-6 [12093007.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2926-31 [12351404.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):121-7 [12491513.001]
  • [Cites] Melanoma Res. 2003 Jun;13(3):219-29 [12777975.001]
  • [Cites] J Clin Invest. 2003 Jul;112(2):170-80 [12865406.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):821-4 [14607831.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7368-76 [15187113.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 1;96(17):1331-42 [15339971.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):737-45 [15373779.001]
  • [Cites] Cancer. 1986 Apr 15;57(8 Suppl):1675-7 [3512072.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] EMBO J. 1995 Jun 15;14(12):2816-26 [7796808.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):7-17 [8558223.001]
  • [Cites] J Biol Chem. 1997 Nov 7;272(45):28779-85 [9353349.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S35-42 [9578415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 [9636188.001]
  • [Cites] Nat Biotechnol. 2004 Dec;22(12):1546-53 [15558048.001]
  • [Cites] Leukemia. 2005 Feb;19(2):209-13 [15618960.001]
  • [Cites] J Immunol Methods. 2005 Jan;296(1-2):115-23 [15680156.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3447-53 [15833880.001]
  • [Cites] Nat Rev Immunol. 2005 May;5(5):375-86 [15864272.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):722-9 [15951814.001]
  • [Cites] Melanoma Res. 2005 Dec;15(6):481-8 [16314732.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3164-71 [16809739.001]
  • [Cites] Nat Rev Immunol. 2006 Nov;6(11):836-48 [17063185.001]
  • [Cites] Int J Oncol. 2007 Mar;30(3):689-94 [17273770.001]
  • [Cites] Mol Cancer Res. 2007 Mar;5(3):271-81 [17374732.001]
  • [Cites] J Immunol. 2007 Apr 15;178(8):4832-45 [17404264.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5025-32 [17510435.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):231-7 [17579625.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5010-9 [17785551.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1650-5 [18754879.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9634-42 [19047140.001]
  • [Cites] Semin Cell Dev Biol. 2008 Aug;19(4):341-50 [18621135.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2505-10 [10851049.001]
  • (PMID = 20398276.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA95426; United States / NCI NIH HHS / CA / K24 CA093670; United States / NCI NIH HHS / CA / K24 CA93670; United States / NCI NIH HHS / CA / P30 CA16058; United States / NCI NIH HHS / CA / CA84402; United States / NCI NIH HHS / CA / K22 CA134551; United States / NCI NIH HHS / CA / P30 CA016058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / RNA, Small Interfering; 0 / Recombinant Proteins; 0 / SOCS1 protein, human; 0 / SOCS3 protein, human; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; 82115-62-6 / Interferon-gamma; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC2858748
  •  go-up   go-down


95. Kim H, Park JH, Shin SJ, Kim MJ, Bang SJ, Park NH, Nah YW, Nam CW, Joo KR, Min YJ: Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study. Chemotherapy; 2008;54(1):54-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
  • The standard beneficial chemotherapy proven for patients with advanced pancreatic cancer is a regimen containing gemcitabine.
  • Eligibility criteria were pathologically proven, chemotherapy-naïve, and metastatic or nonoperable advanced pancreatic cancer.
  • Combination chemotherapy including FDRI of gemcitabine seems minimally active for patients with advanced, nonoperable pancreatic cancer.
  • Further research to improve effectiveness of chemotherapy for advanced pancreatic cancer is mandatory.

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 18073472.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


96. Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, Goldenberg DM: A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med; 2005 Apr;46(4):620-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
  • This trial determined the pharmacokinetics, dosimetry, and dose-limiting toxicity of 90Y-hMN-14 IgG (humanized anticarcinoembryonic antigen [CEA, or CEACAM5] monoclonal antibody; labetuzumab), combined with doxorubicin and peripheral blood stem cell (PBSC) support in advanced medullary thyroid cancer (MTC) patients.
  • Evidence of antitumor response in these patients with advanced cancer was modest, but encouraging; this type of treatment may be more successful if applied to more limited, earlier-stage disease.

  • Genetic Alliance. consumer health - Thyroid cancer, medullary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809485.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA79857; United States / FDA HHS / FD / FD-R-001555-01
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radiopharmaceuticals
  •  go-up   go-down


97. Scorsetti M, Navarria P, Mancosu P, Alongi F, Castiglioni S, Cavina R, Cozzi L, Fogliata A, Pentimalli S, Tozzi A, Santoro A: Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc. Radiat Oncol; 2010;5:94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc.
  • BACKGROUND: To report acute toxicity, initial outcome results and planning therapeutic parameters in radiation treatment of advanced lung cancer (stage III) with volumetric modulated arcs using RapidArc (RA).
  • All showed locally advanced non-small cell lung cancer with stage IIIA-IIIB and with large volumes (GTV:299 ± 175 cm3, PTV:818 ± 206 cm3).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Organs at Risk / radiation effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Oncol. 2008;3:24 [18782447.001]
  • [Cites] Radiother Oncol. 2008 Apr;87(1):17-23 [18343515.001]
  • [Cites] Radiother Oncol. 2008 Dec;89(3):254-62 [18760851.001]
  • [Cites] Acta Oncol. 2009;48(2):227-32 [18855157.001]
  • [Cites] Eur J Cancer. 2009 Apr;45(6):931-91 [19171476.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):252-9 [19362244.001]
  • [Cites] Radiother Oncol. 2009 Jun;91(3):438-42 [19368985.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1570-7 [19880261.001]
  • [Cites] Cancer. 2010 Jan 1;116(1):241-50 [19918925.001]
  • [Cites] Radiother Oncol. 2010 Jan;94(1):67-70 [20022395.001]
  • [Cites] Radiat Oncol. 2010;5:14 [20170490.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):942-9 [20381267.001]
  • [Cites] Radiat Oncol. 2010;5:54 [20550722.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Chest. 2000 Feb;117(2):358-64 [10669675.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):127-36 [11134205.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):23-33 [11163494.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):70-8 [12576928.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1268-79 [15001272.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):741-7 [15465190.001]
  • [Cites] N Engl J Med. 1990 Oct 4;323(14):940-5 [2169587.001]
  • [Cites] J Natl Cancer Inst. 1991 Mar 20;83(6):417-23 [1847977.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Med Phys. 1998 May;25(5):656-61 [9608475.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):1-9 [9747813.001]
  • [Cites] Cancer. 2005 May 15;103(10):2118-27 [15830346.001]
  • [Cites] Med Phys. 2006 Aug;33(8):2839-51 [16964860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):531-40 [17398035.001]
  • [Cites] Med Phys. 2008 Jan;35(1):310-7 [18293586.001]
  • [Cites] Radiother Oncol. 2008 Nov;89(2):180-91 [18692929.001]
  • (PMID = 20950469.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2972299
  •  go-up   go-down


98. Brown DJ, McMillan DC, Milroy R: The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer; 2005 Jan 15;103(2):377-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer.
  • BACKGROUND: Functional disability is reported frequently in fatigued cancer patients, but little is known about the correlation between fatigue and objective physical function.
  • METHODS: Thirty-eight patients with metastatic or locally advanced lung carcinoma and 15 age-matched and gender-matched, healthy controls completed the Functional Assessment of Chronic Illness Therapy-Fatigue scale, a visual analogue weakness score, and the Hospital Anxiety and Depression (HAD) scale.
  • The cancer patients were then grouped into tertiles on the basis of fatigue scores.
  • RESULTS: The cancer patients had greater fatigue compared with the control group (P < 0.001).
  • CONCLUSIONS: Objective physical function (as measured by chair-rise time) in patients with advanced lung cancer was poorer with increasing fatigue.
  • [MeSH-major] Depressive Disorder / epidemiology. Fatigue / epidemiology. Lung Neoplasms / epidemiology. Lung Neoplasms / pathology. Neoplasm Invasiveness / pathology. Quality of Life
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Analysis of Variance. Anxiety / diagnosis. Anxiety / epidemiology. Case-Control Studies. Cohort Studies. Comorbidity. Exercise Tolerance / physiology. Female. Humans. Incidence. Inflammation / diagnosis. Inflammation / epidemiology. Karnofsky Performance Status. Male. Middle Aged. Muscle Weakness. Neoplasm Staging. Pain Measurement. Probability. Reference Values. Risk Assessment. Severity of Illness Index. Sex Distribution. Statistics, Nonparametric. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • [CommentIn] Cancer. 2005 Jan 15;103(2):213-5 [15558821.001]
  • (PMID = 15558809.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Wu ZY, Wan J, Yao Y, Zhao G, Du JL, Yang J: [Clinic study of lateral lymph node metastasis in advanced lower rectal cancer]. Zhonghua Wai Ke Za Zhi; 2008 Feb 1;46(3):190-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinic study of lateral lymph node metastasis in advanced lower rectal cancer].
  • OBJECTIVE: To evaluate the risk factors of lateral lymph node metastasis in advanced lower rectal cancer and its correlation with local recurrence and prognosis.
  • METHODS: Data from 96 consecutive patients with advanced lower rectal cancer underwent curative surgery with lateral dissection were retrospectively analyzed.
  • CONCLUSIONS: Tumor diameter, degree of tumor infiltration and histological differentiation are significant risk factors of lateral lymph node metastasis in advanced lower rectal cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683713.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


100. [Reconstruction of the chest using titanium devices after extensive resection of ribs and breast bone in cancer patients]. Vopr Onkol; 2010;56(3):301-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction of the chest using titanium devices after extensive resection of ribs and breast bone in cancer patients].
  • Access to surgical treatment can be extended to more advanced cancer sufferers through plastic surgery, thus contributing to better quality of life and longer survival.

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20804051.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] D1JT611TNE / Titanium
  •  go-up   go-down






Advertisement